[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 129
1. Kim SH, Lim JH, Lee WJ, Lim HK: Macrocystic pancreatic lesions: differentiation of benign from premalignant and malignant cysts by CT. Eur J Radiol; 2009 Jul;71(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrocystic pancreatic lesions: differentiation of benign from premalignant and malignant cysts by CT.
  • OBJECTIVE: To assess useful CT features for differentiating benign from premalignant and malignant macrocystic pancreatic lesions.
  • METHODS: Seventy-four patients with pathologically proven macrocystic pancreatic lesions were enrolled: 17 benign cysts (macrocystic serous cystadenoma, n=12; congenital cyst; n=5) and 57 premalignant and malignant cysts (mucinous cystic neoplasm, n=28; intraductal papillary mucinous neoplasm of branch duct type, n=20; tumor with cystic change, n=9).
  • RESULTS: On univariate analysis, the differences for the shape (p=0.007), wall thickness (p=0.011), and internal surface (p=0.012) between benign and premalignant and malignant cysts were significant.
  • A lobulated shape, a thin wall and a smooth internal surface were more frequent in benign cysts, whereas a round or oval shape or a complex cystic shape with tubular cyst, a thick wall and an irregular internal surface were more frequent in premalignant and malignant cysts.
  • On multivariate analysis, the shape (p=0.002) and wall thickness (p=0.025) were significant CT features for differentiating benign from premalignant and malignant cysts.
  • CONCLUSION: Shape and wall thickness are the main CT features for differentiating benign from premalignant and malignant macrocystic pancreatic lesions.
  • [MeSH-major] Algorithms. Pancreatic Cyst / radiography. Pancreatic Neoplasms / radiography. Precancerous Conditions / radiography. Radiographic Image Interpretation, Computer-Assisted / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448299.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


2. Barakat O, Rodriguez GC, Raijman I, Allison PM, Nieto J, Ozaki CF, Wood RP, Engler DA: Clinical value of plasma hepatocyte growth factor measurement for the diagnosis of periampullary cancer and prognosis after pancreaticoduodenectomy. J Surg Oncol; 2010 Dec 1;102(7):816-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Of the patients enrolled in this pilot study (n = 118), 57 had PAC, 21 had benign pancreatic tumor (BPT), 20 had chronic pancreatitis (CP), and 20 were healthy controls.
  • CONCLUSIONS: Plasma HGF level discriminates well between PAC and other, benign diseases.
  • Therefore, HGF measurement could be a useful addition to the existing array of diagnostic tools for PAC pancreatic cancer.
  • [MeSH-major] Ampulla of Vater / pathology. Biomarkers, Tumor / blood. Common Bile Duct Neoplasms / blood. Hepatocyte Growth Factor / blood. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Postoperative Period. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20812348.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


3. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • SUMMARY BACKGROUND DATA: Pancreatic IPMNs are increasingly recognized, often as incidental findings, especially in people over age 70 and 80.
  • Computed tomography (CT) and magnetic resonance (MR) are unreliable in discriminating a benign from a malignant neoplasm.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • Forty-two patients underwent pancreatic resection, 2 palliative surgery, and 20 did not undergo surgery.
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • CONCLUSIONS: 18-FDG PET is more accurate than conventional imaging techniques (CT and MR) in distinguishing benign from malignant (invasive and noninvasive) IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Yamaguchi K, Nakano K, Nagai E, Chijiiwa K, Kinoshita M, Ohta M, Tanaka M: Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepatogastroenterology; 2005 May-Jun;52(63):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
  • BACKGROUND/AIMS: The differentiation between benign and malignant jaundice is sometimes difficult even with modern diagnostic modalities.
  • With recent advances in molecular biology, Ki-ras point mutation in codon 12 and p53 mutation have been reported as novel biomarkers of hepatobiliary and pancreatic carcinoma.
  • The purpose of this study was to compare exfoliative bile cytology and biomarkers of the bile in patients with hepatobiliary and pancreatic diseases.
  • METHODOLOGY: Cytologic examination and novel biomarkers, point mutations of codon 12 of Ki-ras and p53 mutations, were examined in the biliary tract bile aspirated through percutaneous transhepatic biliary drainage (PTBD) tube in 30 Japanese patients with benign and malignant hepatobiliary and pancreatic diseases.
  • CONCLUSIONS: These findings suggest that genetic examinations of the bile, when used in conjunction with cytology, may improve the diagnostic yield for suspected malignant tumors of the hepatobiliary and pancreatic system.
  • [MeSH-major] Bile / cytology. Bile Duct Neoplasms / genetics. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Biomarkers, Tumor / genetics. Codon / genetics. DNA Mutational Analysis. Genes, ras / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Diseases / diagnosis. Bile Duct Diseases / genetics. Female. Humans. Male. Middle Aged. Pancreatic Diseases / diagnosis. Pancreatic Diseases / genetics. Point Mutation. Reference Values. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966189.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Codon; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


5. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • For this reason, pancreatic cysts with mucinous differentiation ought to be evaluated carefully, preferably by experts familiar with subtle evidences of malignancy in these tumors.
  • In contrast, the rare cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia such as the rare cystic ductal adenocarcinomas, cystic endocrine neoplasia, and most importantly, solid-pseudopapillary tumor (SPT) in which cystic change is so common that it used to be incorporated into its name ("solid-cystic," "papillary-cystic") are malignant neoplasia, albeit variable degrees of aggressiveness.
  • SPT holds a distinctive place among pancreatic neoplasia because of its highly peculiar characteristics, undetermined cell lineage, occurrence almost exclusively in young females, association with beta-catenin pathway, and also by being a very low-grade curable malignancy.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


6. Jang JY: [Surgical management of intraductal papillary mucinous neoplasms]. Korean J Gastroenterol; 2008 Oct;52(4):220-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With increasing indence and peculiar clinico-pathological features, intraductal papillary mucinous neoplasm (IPMN) of the pancreas has been a major interest in the field of pancreatology.
  • Although pathologic and clinical diversities make difficulty in decision of treatment of IPMN in some circumstances, surgical treatment is generally indicated for main duct IPMN and branch duct IPMN with suspected malignancy (tumor size > or = 30 mm, mural nodules, dilated main pancreatic duct, or positive cytology) or prominent symptoms.
  • However, invasive IPMN shows poor prognosis comparable to stage-matched pancreatic ductal adenocarcinoma.
  • Conventional pancreatic resection is recommended in case of highly suspected malignant cases, and organ preserving pancreatectomy or minimal invasive surgery could be used, especially in benign looking branch duct IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077523.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 18
  •  go-up   go-down


7. Mizumoto M, Honjo G, Kobashi Y, Nishimura S, Nakamura Y, Yoshimura T, Awane M, Kato Y, Furuyama H, Asao Y, Maeda H, Takakuwa H, Matsusue S: Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: Forty-three intraductal papillary mucinous neoplasms were divided into 3 duct ectatic types using preoperative images (the main duct type, the branch duct type, and the mixed type), and into 2 groups using resected specimens (the malignant group including severe dysplasia based on the WHO classification and the benign group).
  • The diameters of the tumor, main pancreatic duct and mural nodule were measured on the images.
  • RESULTS: Two thirds of main duct type cases were in the malignant group.
  • For the branch duct and mixed types, the diameters of the tumor and detectable mural nodules were larger in the malignant group than in the benign group.
  • A tumor diameter larger than 3.5cm and a mural nodule diameter larger than 6mm were risk factors for malignancy (p < 0.05).
  • CONCLUSIONS: The main duct type, a tumor larger than 3.5cm of the branch duct or mixed type, and a mural nodule larger than 6mm were all indicators of malignancy risk.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613438.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Ito K, Taira K, Arii S: Intrahepatic bile duct dilatation with a liver cyst and hemangioma: report of a case. Surg Today; 2009;39(3):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic bile duct dilatation with a liver cyst and hemangioma: report of a case.
  • We report a case of intrahepatic bile duct dilatation with a liver cyst and hemangioma.
  • A 58-year-old woman was referred for investigation of a cystic lesion and peripheral intrahepatic bile duct dilatation in the left lateral segment of the liver.
  • Microscopically, the cyst was lined with a single layer of flattened epithelial cells and a spongy tumor was diagnosed as cavernous hemangioma, which compressed the bile duct.
  • Invasive surgery may be avoided by awareness of this unusual benign pathology.


9. Andersson M, Kostic S, Johansson M, Lundell L, Asztély M, Hellström M: MRI combined with MR cholangiopancreatography versus helical CT in the evaluation of patients with suspected periampullary tumors: a prospective comparative study. Acta Radiol; 2005 Feb;46(1):16-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To establish the diagnostic accuracy of MRI including MR cholangiopancreatography (MRCP) compared with helical CT in the differentiation of malignant and benign lesions in the periampullary region.
  • MATERIAL AND METHODS: Fifty-one patients (27 M, 24 F, mean age 66 years, range 39-86 years) with obstructive jaundice and sonographic evidence of intra- and extrahepatic bile duct dilatation (n=31) or suspicion of periampullary tumor, based on previously performed ultrasound and/or CT examination (n=20), were studied.
  • Lesion status (differentiation of malignant versus benign) was rated on a 5-point diagnostic confidence scale.
  • CONCLUSION: MRI with MRCP was significantly more accurate than CT in differentiating between malignant and benign lesions in patients with suspected periampullary tumors, mainly due to the information obtained on the MRCP images of the biliary and pancreatic duct anatomy.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / radiography. Cholangiopancreatography, Magnetic Resonance. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / radiography. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841735.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


10. Colovic RB, Grubor NM, Micev MT, Atkinson HD, Rankovic VI, Jagodic MM: Cystic lymphangioma of the pancreas. World J Gastroenterol; 2008 Nov 28;14(44):6873-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma of the pancreas is an extremely rare benign tumour of lymphatic origin, with fewer than 60 published cases.
  • Complete excision is curative, even though, depending on the tumour location, surgery may be simple or involve extensive pancreatic resection and anastomoses.
  • At surgery, a well circumscribed polycystic tumor was completely excised, with preservation of the pancreatic duct.
  • Although extremely rare, lymphangioma of the pancreas should be taken into consideration as a differential diagnosis of a pancreatic cystic lesion, especially in women.
  • [MeSH-major] Lymphangioma, Cystic / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2001;31(8):743-6 [11510617.001]
  • [Cites] J Formos Med Assoc. 2006 Jun;105(6):512-7 [16801041.001]
  • [Cites] Eur Radiol. 2001;11(11):2232-5 [11702164.001]
  • [Cites] Arch Pathol Lab Med. 2003 Nov;127(11):1513-6 [14567749.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1681-6 [14571816.001]
  • [Cites] Radiology. 1977 Mar;122(3):636 [841038.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):503-10 [3618222.001]
  • [Cites] J Chir (Paris). 1989 Dec;126(12):650-8 [2695531.001]
  • [Cites] Eur J Surg. 1993 Sep;159(9):499-501 [8274560.001]
  • [Cites] J Clin Gastroenterol. 1995 Mar;20(2):142-4 [7769196.001]
  • [Cites] Postgrad Med J. 1996 Sep;72(851):564-6 [8949598.001]
  • [Cites] Abdom Imaging. 1998 Jan-Feb;23(1):78-80 [9437068.001]
  • [Cites] Acta Chir Belg. 1997 Dec;97(6):297-8 [9457321.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] AJR Am J Roentgenol. 2001 Nov;177(5):1090 [11641176.001]
  • (PMID = 19058318.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC2773887
  •  go-up   go-down


11. Evert M, Schildhaus HU, Schneider-Stock R, Dombrowski F: Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats. Virchows Arch; 2006 Jun;448(6):776-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats.
  • In our study, we investigated the effect of the transplantation of a low number (n = 350) of pancreatic islets into the right liver part on the neighboring portal bile ducts.
  • During the next 12-24 months, many peri-insular ductules progressed via tumor-like cystic lesions to large cystic cholangiomas, accompanied by a translocation of the insulin receptor into the cytoplasm and an increase in expression of insulin-related signaling proteins (Insulin-receptor-substrate-1, Raf-1, Mek-1).
  • After 24 months, 53% of rats with low-number transplantation exhibited at least one cholangioma >10 mm, significantly outnumbering tumor development in the transplant-free left liver part and in any control group.
  • Conclusively, low-number intrahepatic islet transplantation, most likely acting by permanent local hyperinsulinism, leads to prolonged cholangiocellular proliferation in streptozotocin- and in autoimmune-diabetic rats, resulting in the development of benign cystic cholangiomas.
  • [MeSH-major] Adenoma, Bile Duct / etiology. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic / pathology. Diabetes Mellitus, Experimental / complications. Diabetes Mellitus, Type 1 / complications. Islets of Langerhans Transplantation / adverse effects


12. Huis M, Stulhofer M, Szerda F, Vukić T, Bubnjar J: [Obstruction icterus--our experience]. Acta Med Croatica; 2006;60(1):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The most common causes of extrahepatic obstruction are choledocholithiasis, malignant and benign stenosis of biliary ducts, pancreatic head carcinoma, and chronic cephalic pancreatitis.
  • Intraoperative lesion occurring on biliary duct procedures is generally involved in the etiology of benign stenoses of extrahepatic biliary ducts.
  • Biliodigestive anastomosis was created in another 20 patients with the findings of inoperable tumor of the head of pancreas, inoperable tumor of the papilla of Vater, postoperative choledochus stenosis, stenosis of choledochoduodenal anastomosis, and chronic cephalic pancreatitis.
  • Operative treatment can be fully successful in cases caused by lithiasis or benign stenosis, whereas in cases due to malignant disease a variety of radical and operative procedures associated with a variable level of success are available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802577.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


13. Lapkus O, Gologan O, Liu Y, Swalsky PA, Wilson MM, Finkelstein SD, Silverman JF: Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol; 2006 Jul;19(7):907-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology.
  • Neoplastic progression is characterized by clonal expansion of tumor cells associated with accumulation of mutational damage.
  • The timing of mutation acquisition could be of value in distinguishing preneoplastic conditions from early and advanced cancer as well as characterizing tumor aggressiveness and treatment response.
  • In all, 40 pancreatic duct and 21 biliary brushing cytology specimens were retrieved from the cytology database.
  • Clusters of benign, atypical and malignant cells were manually microdissected and DNA extracted.
  • The descending frequency of detectable mutational involvement in pancreatic cytology was K-ras-2 point mutation (58%), 3p25-26 and 17q21 (35%), 5q23 (33%), 1p36 (28%), followed by the remaining molecular markers.
  • The descending frequency of mutational content in bile duct cytology was 17p13, 1p36, 3p25-26, and 5q23 followed by remaining molecular markers.
  • K-ras-2 point mutation was not seen in bile duct specimens.
  • While there was overlap in the spectrum of mutational markers in pancreatic duct and biliary brushing cytology, the temporal profile was significantly different (P<0.001).
  • Pancreatic and biliary neoplasia progression involves distinct subset of accumulated defined mutations.
  • [MeSH-major] Biliary Tract Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Mutation. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648872.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


14. Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, Corradini SG, Invernizzi P, Franchitto A, Attili AF, Gaudio E, Benedetti A: Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med; 2007 Oct 2;147(7):451-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: 73 patients who consecutively had endoscopic retrograde cholangiopancreatography (ERCP), including patients with extrahepatic cholangiocarcinoma (n = 29), pancreatic cancer (n = 19), and benign biliary abnormalities (n = 25; bile duct stones, primary sclerosing cholangitis, and cholangitis).
  • RESULTS: The biliary IGF-I concentration was 15- to 20-fold higher (P < 0.001) in extrahepatic cholangiocarcinoma (mean, 84.6 nmol/L [95% CI, 74.0 to 95.2 nmol/L]) than in pancreatic cancer (5.8 nmol/L [CI, 4.0 to 7.5 nmol/L]) or benign biliary abnormalities (4.1 nmol/L [CI, 3.1 to 5.2 nmol/L]).
  • The area under the receiver-operating characteristic curve was 1 when biliary IGF-I values in the extrahepatic cholangiocarcinoma were compared with benign biliary abnormalities or pancreatic cancer.
  • Serum IGF-I levels were similar among the groups, whereas serum VEGF levels were higher in the cholangiocarcinoma (0.97 ng/mL [CI, 0.59 to 1.35 ng/mL]; P = 0.0016) and pancreatic cancer groups (0.66 ng/mL [CI, 0.43 to 0.88 ng/mL]; P < 0.001) compared with patients with benign biliary abnormalities (0.28 ng/mL [CI, 0.17 to 0.37 ng/mL]).
  • CONCLUSIONS: Biliary IGF-I levels in patients undergoing ERCP for biliary obstruction may differentiate extrahepatic cholangiocarcinoma from either pancreatic cancer or benign biliary abnormalities.
  • [MeSH-major] Bile / chemistry. Bile Duct Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Cholangiocarcinoma / diagnosis. Cholestasis / etiology. Insulin-Like Growth Factor I / analysis. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Biliary Tract Diseases / complications. Biliary Tract Diseases / diagnosis. Cross-Sectional Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / diagnosis. ROC Curve

  • Genetic Alliance. consumer health - Cholestasis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Intern Med. 2007 Nov 6;147(9):676
  • (PMID = 17909206.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


15. Liu Y, Lin X, Upadhyaya M, Song Q, Chen K: Intraductal papillary mucinous neoplasms of the pancreas: correlation of helical CT features with pathologic findings. Eur J Radiol; 2010 Nov;76(2):222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the CT features of intraductal papillary mucinous neoplasms of the pancreas (IPMNs), and to compare with pathological findings in order to identify CT features that can be helpful in differentiating benign IPMNs from malignant IPMNs.
  • MATERIALS AND METHODS: The CT findings in 25 patients were reviewed for tumor location, tumor type, dilatation of the main pancreatic duct (MPD), MPD involvement, mural node or solid attenuating component, tumor size in branch duct or mixed duct type, dilatation of common bile duct (CBD) and invasion of surrounding structures.
  • None of tumor location, tumor type, dilatation of MPD, MPD involvement, tumor size, and invasion of surrounding structures was statistically significant in differentiating benign from malignant IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiography. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19586733.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


16. Takeshita K, Kutomi K, Takada K, Haruyama T, Fukushima J, Aida R, Takada T, Furui S: Differential diagnosis of benign or malignant intraductal papillary mucinous neoplasm of the pancreas by multidetector row helical computed tomography: evaluation of predictive factors by logistic regression analysis. J Comput Assist Tomogr; 2008 Mar-Apr;32(2):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign or malignant intraductal papillary mucinous neoplasm of the pancreas by multidetector row helical computed tomography: evaluation of predictive factors by logistic regression analysis.
  • OBJECTIVE: The purpose of this study is to evaluate predictive factors for discriminating benign from malignant intraductal mucin-producing neoplasm (IPMN) of the pancreas on multidetector row computed tomography (MDCT).
  • In patients with branch duct-type tumors, sex and age of the patient, location, shape, size and multiplicity of the cystic lesion, presence of mural nodule, and maximum diameter of main pancreatic duct (MPD) dilatation were evaluated by logistic regression analysis.
  • RESULTS: Tumors were classified as main duct-type (n = 7) and branch duct-type (n = 46).
  • Among main duct-type tumors, all 7 lesions were diagnosed as malignant.
  • Among 46 lesions of branch-type IPMN, 8 lesions were malignant, and 38 lesions were benign.
  • On adjusted logistic regression analysis, combination factor of main duct dilatation and mural nodule or large cystic size had statistical significance for the risk of malignancy in branch duct-type IPMN.
  • CONCLUSIONS: Main duct-type IPMN is highly suggestive for malignancy.
  • Combination factors of main ductal dilation and mural nodule, and main ductal dilation, and large cystic tumor size are thought to be predictive factors for malignant branch-type IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, Spiral Computed / methods. Tomography, Spiral Computed / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379300.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


17. Isayama H: Current topics in pancreato-biliary endotherapy: what can we do? J Hepatobiliary Pancreat Surg; 2009;16(5):589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CMS is effective not only for unresectable biliary malignancies but also for resectable tumors, benign biliary strictures, and benign pancreatic strictures.
  • Drug-eluting CMS can be used as anti-tumor agents.
  • The diagnosis and treatment of pancreatic cancer using interventional EUS technique are effective, feasible, and promising.
  • Endoscopic papillary large balloon dilation (EPLBD), new procedure to the papilla, can treat large bile duct stones effectively without lithotripsy.
  • [MeSH-major] Biliary Tract Diseases / therapy. Biliary Tract Diseases / ultrasonography. Endoscopy, Digestive System / methods. Pancreatic Diseases / therapy. Pancreatic Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543686.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


18. Allen PJ, Qin LX, Tang L, Klimstra D, Brennan MF, Lokshin A: Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg; 2009 Nov;250(5):754-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm.
  • BACKGROUND: Many patients with benign serous cystadenoma (SCA) of the pancreas will undergo resection because of the inability to reliably discriminate between SCA and premalignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous cystic neoplasm [MCN]).
  • METHODS: Cyst fluid from patients with SCA (n = 15), non main-duct and noninvasive IPMN (n = 32), and noninvasive MCN (n = 12) was aspirated at the time of operative resection and analyzed.
  • Commercially available and custom designed multiplex assays (Luminex) were performed using a biomarker panel developed for pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806054.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / U01 CA117452; United States / NCI NIH HHS / CA / U01 CA08496
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS718468; NLM/ PMC4556365
  •  go-up   go-down


19. Iacono C, Bortolasi L, Facci E, Nifosì F, Pachera S, Ruzzenente A, Guglielmi A: The Dagradi-Serio-Iacono operation central pancreatectomy. J Gastrointest Surg; 2007 Mar;11(3):364-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central pancreatectomy (CP) is a segmental pancreatic resection indicated to remove benign or low-grade malignant tumors of the isthmus and proximal part of the body of the pancreas.
  • The main advantage of this operation compared with major resections is that it permits to spare normal pancreatic parenchyma; moreover, spleen and upper digestive and biliary tracts are saved.
  • The pancreatic segment harboring the lesion is then mobilized and its posterior surface carefully dissected from the splenic vein and artery.
  • Subsequently, the pancreatic portion harboring the tumor is isolated at its superior margin from the splenic artery after the pancreas is transacted.
  • The extent of the resection of the central segment is limited on the right by the gastroduodenal artery and on the left by the need to leave at least 5 cm of normal pancreatic remnant.
  • The resected pancreatic specimen is sent to the pathologist for confirmation of diagnosis and to check if the resection margins are adequate.
  • When it is not stapled, the Wirsung's duct of the cephalic stump is sutured selectively with a figure-of-eight nonabsorbable stitch.
  • The operation is concluded with the construction of an end-to-side jejuno-jejunostomy about 50 cm distal to the pancreatic anastomosis.
  • Central pancreatectomy is a safe technique for benign or low malignant tumors of the pancreatic neck that allows curing the tumor with evident functional results without increasing the risk for the patient.
  • We can say that CP has a clear role like pancreaticoduodenectomy and distal pancreatectomy and we think that a pancreatic surgeon has to include this procedure in his/her technical skills.
  • In order to obtain excellent results, correct indications and experience in pancreatic surgery are recommended.
  • [MeSH-minor] Humans. Pancreatic Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Ann Chir. 2002 Jan;127(1):48-54 [11833306.001]
  • [Cites] Chirurg. 1980 May;51(5):303-7 [7408575.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):730-3 [8751242.001]
  • [Cites] World J Surg. 2003 May;27(5):595-8 [12715230.001]
  • [Cites] J Chir (Paris). 1968 Jan;95(1):5-42 [4878838.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):595-8 [15086212.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):898-903 [2179721.001]
  • [Cites] HPB (Oxford). 2006;8(2):142-7 [18333263.001]
  • [Cites] Am J Surg. 2006 Apr;191(4):549-52 [16531153.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):871-6 [15194067.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Surg Gynecol Obstet. 1959 Oct;109:473-8 [14416087.001]
  • [Cites] Int Surg. 2000 Oct-Dec;85(4):297-302 [11589595.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):132-5 [11398167.001]
  • [Cites] Arch Surg. 2006 Apr;141(4):361-5; discussion 366 [16618893.001]
  • [Cites] Surg Today. 1993;23(8):733-6 [8400678.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Chirurg. 2003 Oct;74(10 ):961-5 [14605740.001]
  • [Cites] Chirurg. 2004 Jun;75(6):615-21 [15103421.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] Dig Surg. 2004;21(1):48-53 [14707393.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):293-9 [16549696.001]
  • [Cites] Chirurgie. 1998 Sep;123(4):363-7 [9828510.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2585-8 [10522046.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1023-8 [9261593.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):719 [3416130.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):233-6 [15783038.001]
  • (PMID = 17458612.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Morana G, Guarise A: Cystic tumors of the pancreas. Cancer Imaging; 2006;6:60-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many lesions can cause a pancreatic cyst, most being non-neoplastic while approximately 10% are cystic tumors, ranging from benign to highly malignant tumors.
  • According to the WHO classification, they can be subdivided on the basis of their histological type and biological behavior into benign tumors, borderline tumors, and malignant tumors.
  • Cystic pancreatic tumors can be subdivided into peripheral (serous cystadenomas, mucinous cystic tumors, solid and papillary epithelial neoplasms, cystic islet cell tumors), which do not communicate with the main pancreatic duct, and ductal tumors (mucinous tumor), according to their site of origin.
  • The management of these patients is complex, and it is important to correlate imaging findings with knowledge of the patient's symptoms and of the natural history and predictors of malignancy in pancreatic cysts.
  • [MeSH-major] Cystadenoma / diagnosis. Diagnostic Imaging. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Radiographics. 1999 Nov-Dec;19(6):1447-63 [10555668.001]
  • [Cites] J Comput Assist Tomogr. 1999 Nov-Dec;23(6):906-12 [10589565.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):441-7 [10658722.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):7-15 [10721803.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Acta Radiol. 2000 Jul;41(4):343-7 [10937755.001]
  • [Cites] Ann Chir. 2000 Jul;125(6):571-7 [10986770.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Dig Dis. 2001;19(1):57-62 [11385252.001]
  • [Cites] Eur Radiol. 2001;11(9):1626-30 [11511881.001]
  • [Cites] Eur Radiol. 2001;11(10):1939-51 [11702126.001]
  • [Cites] Abdom Imaging. 2001 Nov-Dec;26(6):640-7 [11907731.001]
  • [Cites] Radiology. 2002 May;223(2):547-53 [11997566.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Oct;12(4):673-96 [12607779.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(2):171-83 [7281507.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Hepatogastroenterology. 1989 Dec;36(6):462-6 [2613167.001]
  • [Cites] Gastrointest Endosc. 1990 Jul-Aug;36(4):410-1 [2210291.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Gastrointest Radiol. 1991 Winter;16(1):53-61 [1991611.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):199-201 [1851710.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):465-71 [2065922.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):634-8 [1317671.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Am Surg. 1993 Nov;59(11):740-5 [7694532.001]
  • [Cites] Curr Probl Surg. 1994 Mar;31(3):165-243 [8168359.001]
  • [Cites] J Comput Assist Tomogr. 1994 May-Jun;18(3):420-6 [8188910.001]
  • [Cites] Radiology. 1996 Jun;199(3):707-11 [8637992.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):714-20 [8799419.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):967-70 [8884322.001]
  • [Cites] Am J Gastroenterol. 1996 Dec;91(12):2548-54 [8946984.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):135-9 [8968870.001]
  • [Cites] Presse Med. 1996 Nov 23;25(36):1794-800 [8991029.001]
  • [Cites] J Comput Assist Tomogr. 1997 May-Jun;21(3):373-82 [9135643.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):887-90 [9149208.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6 [9230804.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):433-49 [9536488.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Radiology. 1998 Jul;208(1):231-7 [9646818.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):554-8 [9734981.001]
  • [Cites] Scand J Gastroenterol. 1998 Aug;33(8):880-9 [9754738.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):467-70 [9931400.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):483-91 [10228848.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):123-33 [10360225.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jun;29(6):294-8 [10418558.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • (PMID = 16861136.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693784
  •  go-up   go-down


21. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg; 2005 Jan;29(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance.
  • [MeSH-major] Carcinoid Tumor / surgery
  • [MeSH-minor] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Breast Neoplasms / surgery. Esophageal Neoplasms / surgery. Female. Gallbladder Neoplasms / surgery. Humans. Laryngeal Neoplasms / surgery. Liver Neoplasms / surgery. Male. Ovarian Neoplasms / surgery. Pancreatic Neoplasms / surgery. Testicular Neoplasms / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):153-8 [8604242.001]
  • [Cites] Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21 [8427027.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):229-35 [7546678.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1705-13 [6383596.001]
  • [Cites] Patol Pol. 1978 Apr-Jun;29(2):237-40 [704186.001]
  • [Cites] N Y State J Med. 1969 May 15;69(10):1337-9 [5255420.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1334-9 [11688471.001]
  • [Cites] Lancet. 1954 Nov 6;267(6845):951 [13213086.001]
  • [Cites] Z Gastroenterol. 1974 Sep;12 Suppl(0):377-84 [4418379.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):897-909 [1707237.001]
  • [Cites] Intern Med. 1996 Dec;35(12 ):953-6 [9030993.001]
  • [Cites] J Urol. 1977 Nov;118(5):777-82 [916100.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2189-95 [10521965.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):398-402 [7647908.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Digestion. 1997;58(4):410-4 [9324172.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Ital J Surg Sci. 1986;16(4):249-53 [3557930.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):259-65 [8626144.001]
  • [Cites] Thorax. 1989 Jul;44(7):594-6 [2672408.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93-5 [7679854.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4209-13 [10566674.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):281-3 [7789401.001]
  • [Cites] Pathol Annu. 1979;14 Pt 1:273-91 [42037.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):217-20 [2776604.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):281-8 [7673859.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):233-8 [9577907.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):141-8 [10713946.001]
  • [Cites] J Urol. 1954 Nov;72(5):892-4 [13212896.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Int J Urol. 2001 Sep;8(9):522-4 [11683977.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] J Am Osteopath Assoc. 2000 Jul;100(7):432-4 [10943090.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1462-7 [9840084.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1073-80 [6644166.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Heart. 1998 Dec;80(6):623-6 [10065036.001]
  • [Cites] Jpn J Clin Oncol. 1989 Dec;19(4):397-401 [2607641.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1959-65 [10570419.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1501-10 [11075851.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):40-3 [11816388.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Ann R Coll Surg Engl. 1959 Dec;25(5):277-97 [19310224.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] Arch Otolaryngol. 1969 Jul;90(1):64-7 [5785991.001]
  • [Cites] Can J Surg. 1999 Feb;42(1):59-63 [10071590.001]
  • [Cites] Acta Cytol. 1990 Mar-Apr;34(2):119-24 [2181800.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):261-4 [9607629.001]
  • [Cites] Diagn Cytopathol. 2001 Sep;25(3):168-71 [11536440.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):589-96 [1587179.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):609-12 [8631405.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):23-32 [14687136.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Arch Anat Pathol (Paris). 1964 Sep;12:200-3 [14228034.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • (PMID = 15599742.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


22. Ku YM, Shin SS, Lee CH, Semelka RC: Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. Top Magn Reson Imaging; 2009 Feb;20(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms.
  • Magnetic resonance imaging is a useful diagnostic modality in the assessment of various pancreatic neoplasms.
  • Pancreatic endocrine tumors are moderately low in signal intensity on T1-weighted fat-suppressed images and moderately high in signal intensity on T2-weighted fat-suppressed images and demonstrate homogeneous, ring, or diffuse heterogeneous enhancement on immediate postgadolinium gradient echo images.
  • Cystic pancreatic neoplasms, including intraductal papillary mucinous neoplasm, are well demonstrated and subcategorized according to their characteristic cystic configurations on MRI and MR cholangiopancreatography images.
  • Mucinous cystic neoplasms usually appear as multilocular cystic masses, with benign forms of macrocystic tumors possessing uniform thickness septations and malignant forms exhibiting irregular septations and tumor nodules.
  • The presence of tumor stroma, invasion of adjacent tissue, or liver metastases can be assessed by MRI.
  • The connection between the pancreatic duct and the cystic tumor is usually well shown on MR cholangiopancreatography images.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Image Enhancement / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687721.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


23. Beger HG, Rau BM, Gansauge F, Schwarz M, Siech M, Poch B: Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure. Langenbecks Arch Surg; 2008 Jul;393(4):589-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure.
  • BACKGROUND: Cystic neoplastic lesions of the pancreas are found in up to 10% of all pancreatic lesions.
  • A malignant transformation of cystic neoplasia is observed in intraductal papillary mucinous tumor (IPMN) lesions in 60% and in mucinous cystic tumor (MCN) lesions in up to 30%.
  • For cystic neoplasia located monocentrically in the pancreatic head and that do not have an association with an invasive pancreatic cancer, the duodenum-preserving total head resection has been used in recent time as a limited surgical procedure.
  • PATIENTS: An indication to duodenum-preserving total pancreatic head resection is considered for patients who do not have clinical signs of an advanced cancer in the lesion and who have main-duct IPMN and monocentric MCN lesions.
  • In 104 patients with cystic neoplastic lesions in the Ulm series, 32% finally had a carcinoma in situ or an advanced pancreatic cancer.
  • The application of a duodenum-preserving total pancreatic head resection in patients with asymptomatic cystic lesion is based on the size of the tumor and the tumor relation to the pancreatic ducts.
  • RESULTS: Duodenum-preserving total pancreatic head resection is used in several modifications.
  • The surgical procedure is a limited pancreatic head resection which necessitates segmental resection of the peripapillary duodenum.
  • The long-term outcome is determined by completeness of resection for both -- benign and malignant -- entities.
  • CONCLUSION: A duodenum-preserving total pancreatic head resection is a limited surgical procedure for patients who suffer a local monocentric, cystic neoplastic lesion in the pancreatic head.
  • Absence of an advanced pancreatic cancer and completeness of extirpation of the benign tumor determine the long-term outcome.
  • In regards to the location of the lesion in the pancreatic head, several modifications have been applied with low hospital morbidity and mortality below 1%.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Cystadenocarcinoma, Mucinous / surgery. Duodenum / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cell Transformation, Neoplastic / pathology. Common Bile Duct / surgery. Frozen Sections. Humans. Neoplasm Invasiveness. Pancreas / pathology. Prognosis. Suture Techniques. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1992-5 [17161189.001]
  • [Cites] Am J Surg. 2001 Feb;181(2):172-6 [11425061.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Pancreas. 2001 Oct;23(3):309-15 [11590328.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):661-7 [11685030.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):533-5 [9638444.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):162-8; discussion 168 [12578411.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):21-5 [12469138.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):923-8; discussion 929-31 [18043093.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Dig Surg. 2004;21(3):242-5 [15237258.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):879-83 [11462947.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):210-2 [9124628.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Surgery. 2003 Jul;134(1):53-62 [12874583.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1379-84 [16105124.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):117-21 [12622422.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):76-85 [12021900.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):610-7; discussion 617-8 [12799331.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Surgery. 2002 May;131(5):577-80 [12019413.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):356-9 [8406305.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Eur J Surg. 2000 Feb;166(2):141-8 [10724492.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):149-56 [18392707.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Chirurg. 1995 Apr;66(4):350-9 [7634946.001]
  • (PMID = 18379818.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Jang JY, Kim SW, Lee SE, Yang SH, Lee KU, Lee YJ, Kim SC, Han DJ, Choi DW, Choi SH, Heo JS, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee HE, Kang GH, Lee JM: Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol; 2008 Jan;15(1):199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe?
  • BACKGROUND: The objectives of this study were to investigate the clinicopathological features of branch intraductal papillary mucinous neoplasm (IPMN) and to determine safe criteria for its observation.
  • Most clinicians agree that surgical resection is required to treat main duct-type IPMN because of its high malignancy rate.
  • However, no definite treatment guideline (with respect to surgery or observation) has been issued on the management of branch duct type IPMN.
  • RESULTS: Of 138 patients (mean age, 60.6 years; 87 men, 51 women), 76 underwent pancreatoduodenectomy, 39 distal pancreatectomy, 4 total pancreatectomy, and 20 limited pancreatic resection.
  • There were 112 benign cases: 47 adenoma, 63 borderline cases, and 26 malignant cases, with 9 of these being noninvasive and 17 invasive.
  • By univariate analysis, tumor size and the presence of a mural nodule were identified as meaningful predictors of malignancy.
  • By receiver operating characteristic curve analysis, a tumor size of >2 cm was found to be the most valuable predictor of malignancy.
  • When cases were classified according to tumor size and the presence of a mural nodule, the malignancy rate for a tumor </=2 cm without a mural nodule was 9.2%, for a tumor of </=2 cm plus a mural nodule was 25%, and for other conditions such as tumor >2 cm, >25%.
  • CONCLUSIONS: Many branch duct IPMNs are malignant.
  • Surgical treatment is recommended, except in cases that are strongly suspected to be benign or cases that present a high operative risk.
  • Observation is only recommended in patients with a tumor size of </=2 cm without a mural nodule.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909912.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Arikawa S, Uchida M, Shinagawa M, Uozumi J, Hayabuchi N, Okabe Y, Suga H, Yanagi K, Kinoshita H, Naitou Y: [The role of multi-detector-row computed tomograph in the diagnosis of intraductal papillary-mucinous tumors of the pancreas in comparison to endoscopic retrograde pancreatography, endoscopic ultrasonography, magnetic resonance cholangiopancreatography]. Nihon Shokakibyo Gakkai Zasshi; 2007 Mar;104(3):373-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty patients with intraductal papillary-mucinous tumor (IPMT) of the pancreas underwent multidetector-row CT (MD-CT) in addition to endoscopic retrograde pancreatography (ERP), and, in 27 cases magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasonography (EUS).
  • The usefulness of MD-CT was investigated by comparing various imaging methods of the communication from the main pancreatic duct (MPD) to patulous/bulging papilla in addition to the indices for benign or malignant disease, the degree of dilation of the MPD, localization and size of cystic lesions, and presence or absence of neoplastic lesions, such as thickened walls and septa, intramural nodule, solid mass.
  • With MD-CT, dilation of the MPD and localization and size of cystic lesions were accurately assessed, even in patients with obstruction of the main pancreatic duct in whom ERP was difficult to perform regardless of the presence or absence of massive amount of mucus.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Diagnostic Imaging / methods. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337874.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Khunamornpong S, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Young RH: Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol; 2007 Dec;31(12):1788-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia.
  • The potential for adenocarcinoma metastatic to the ovary to mimic primary mucinous neoplasms is a well-known issue to surgical pathologists, most of the recent literature emphasizing pancreatic and various other origins for the ovarian metastases.
  • Foci often mimicked mucinous borderline tumors of typical type or with intraepithelial carcinoma and benign-appearing mucinous epithelium was seen in 62% of tumors.
  • Intrahepatic cholangiocarcinoma should be included in the list of origins of possible ovarian metastatic tumors that mimic primary ovarian mucinous neoplasia, particularly in parts of the world where cholangiocarcinoma of the liver is relatively common.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / secondary. Ovarian Neoplasms / secondary


27. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, Mitsuhashi N, Takeuchi D, Takayashiki T, Suda K, Miyazaki M: Surgical strategy for mucin-producing bile duct tumor. J Hepatobiliary Pancreat Sci; 2010 May;17(3):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategy for mucin-producing bile duct tumor.
  • Tumors with copious mucin production within the intra- or extrahepatic bile ducts have been reported as mucin-producing bile duct tumors (MPBTs).
  • Because mucin produced by these tumors causes recurrent cholangitis and obstructive jaundice, surgical resection should be indicated even if these tumors are regarded as benign.
  • In order to choose the appropriate surgical procedure, exact preoperative assessment of tumor location and cancer extension is important, especially evaluation of the extent of superficial spreading through cholangioscopic observation and biopsy.
  • In principle, MPBTs should be resected in a manner similar to that employed for other types of bile duct carcinomas.
  • That is, major hepatectomy with or without extrahepatic bile duct resection or pancreaticoduodenectomy should be chosen as the surgical procedure, and intraoperative frozen section at the stumps of the bile duct is essential.
  • All ten patients with MPBT resected at our institution according to these strategies are still alive without tumor recurrence, with a median survival of 48.0 months.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Mucins / secretion
  • [MeSH-minor] Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Digestive System Surgical Procedures. Hepatectomy. Humans. Neoplasm Invasiveness. Pancreaticoduodenectomy. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19649559.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 20
  •  go-up   go-down


28. Zhou JP, Dong M, Zhang Y, Kong FM, Guo KJ, Tian YL: Giant mucinous biliary cystadenoma: a case report. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):101-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Biliary cystadenoma is a very rare cystic neoplasm of the liver.
  • Gross examination showed that the tumor almost occupied.
  • Pathologically, additional lobulated spaces were seen in the tumor with a lot of mucusa.
  • The interior wall was lined with bile duct tissue, indicating a benign mucinous biliary cystadenoma.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / surgery

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287176.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Kuruma S, Kamisawa T, Tu Y, Egawa N, Tsuruta K, Tonooka A, Funata N: Hemosuccus pancreaticus due to intraductal papillary-mucinous carcinoma of the pancreas. Clin J Gastroenterol; 2009 Feb;2(1):27-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old female was referred to our hospital for evaluation of a hyperechoic mass in the pancreatic head with ultrasound sonography.
  • Endoscopic retrograde pancreatography revealed an irregular defect in the main pancreatic duct at the head of the pancreas.
  • On suspicion of malignant tumor of the pancreas, pylorus-preserving pancreaticoduodenectomy was performed.
  • It grew within the inferior branch of the main pancreatic duct, and the top of the tumor stood out into the main pancreatic duct.
  • As the causes of hemosuccus pancreaticus, pancreatic benign diseases, for example, chronic pancreatitis, pseudocyst, arterial aneurysm and pseudoaneurysm, are known, but pancreatic tumors are rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2000 Aug 1;56(2):211-5 [10925080.001]
  • [Cites] Pancreas. 2007 Mar;34(2):229-32 [17312462.001]
  • [Cites] Gastroenterol Clin Biol. 1994;18(12 ):1142-5 [7750689.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Oct;94(10):706-11 [9391335.001]
  • (PMID = 26191804.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Hemosuccus pancreaticus / Intraductal papillary-mucinous carcinoma without mucin hypersecretion / Pancreas
  •  go-up   go-down


30. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0%; mCEA, 0%; HER2/neu, 12%; mesothelin, 0%; loss of Dpc4, 0%) or BDH (CK20, 10%; p53, 0%; TAG-72, 0%; mCEA, 10%; HER2/neu, 0%; mesothelin, 0%; loss of Dpc4, 0%).
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • Although none of the BDA or BDH was positive for either p63 or AMACR, two of the metastatic pancreatic adenocarcinomas (8%) were positive for each of these peptides (P > 0.05).
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques


31. Thelen A, Neuhaus P: Liver transplantation for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg; 2007;14(5):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Owing to disappointing long-term results for this indication, and in parallel, encouraging results in patients with benign disease, hilar cholangiocarcinoma has generally not been accepted as an indication for liver transplantation in recent years.
  • To improve results, more aggressive approaches have been used: "abdominal organ cluster transplantation" and "extended bile duct resection", which lead to increased long-term survival rates.
  • However, with improving results after conventional extrahepatic bile duct resection in combination with partial hepatectomy, extended procedures in combination with liver transplantation never became a real option in the treatment of hilar cholangiocarcinoma.
  • Current results show increased survival figures, in particular in well-selected patients with early tumor stages.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Liver Transplantation


32. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg; 2008 Aug;207(2):210-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: We analyzed patient demographics, presentation, survival (mean followup 44 months), and tumor histology for 157 consecutive ampullary tumors resected from 1989 to 2006.
  • RESULTS: There were 33 benign (32 adenomas and 1 paraganglioma) and 124 malignant (118 adenocarcinomas and 6 neuroendocrine) tumors.
  • Size of tumor did not predict survival, nor did cribriform/papillary features, dirty necrosis, apical mucin, or nuclear atypia.
  • CONCLUSIONS: In addition to other factors, tumor type (intestinal versus pancreaticobiliary) had a major effect on survival in patients with ampullary adenocarcinoma.
  • The current concept of ampullary adenocarcinoma as a unique entity, distinct from duodenal and pancreatic adenocarcinoma, might be wrong.
  • Intestinal ampullary adenocarcinomas behaved like their duodenal counterparts, but pancreaticobiliary ones were more aggressive and behaved like pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Jaundice, Obstructive / mortality. Jaundice, Obstructive / pathology. Jaundice, Obstructive / surgery. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656049.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Nakayama Y, Inoue H, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Iwanaga S, Tani H, Ryu S, Yasunami Y, Ikeda S: Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases. Am J Surg Pathol; 2005 May;29(5):607-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intraductal tubular adenoma (ITA), pyloric gland type, of the pancreas is an uncommon benign tumor, akin to the pyloric gland type adenoma of the gallbladder.
  • Grossly, all tumors formed a localized polypoid mass protruding into the lumen of the dilated pancreatic duct.
  • Five of the six tumors were found within the main duct, and the other arose within the branch duct of the pancreas.
  • [MeSH-major] Adenoma / pathology. Gastric Mucosa / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Epithelial Cells / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucins / analysis. Mucins / classification. Pancreaticoduodenectomy. Pepsinogen A / analysis. Smad4 Protein. Trans-Activators / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832084.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Mucins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


34. Püspök A, Lomoschitz F, Dejaco C, Hejna M, Sautner T, Gangl A: Endoscopic ultrasound guided therapy of benign and malignant biliary obstruction: a case series. Am J Gastroenterol; 2005 Aug;100(8):1743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound guided therapy of benign and malignant biliary obstruction: a case series.
  • OBJECTIVES: Endoscopic retrograde cholangiography is an established method for treatment of common bile duct stones as well as for palliation of patients with malignant pancreaticobiliary strictures.
  • It may be unsuccessful in the presence of a complex peripapillary diverticulum, prior surgery, obstructing tumor, papillary stenosis, or impacted stones.
  • METHODS: The EUS guided transduodenal puncture of the common bile duct with stent placement was performed in 5 patients.
  • In 2 of these patients, the stents were removed after several weeks and common bile duct stones were extracted.
  • In another patient with gastrectomy, the left intrahepatic bile duct was punctured transjejunally and a metal stent was introduced transhepatically to bridge a distal common bile duct stenosis.
  • CONCLUSIONS: Interventional EUS guided biliary drainage is a new technique that allows drainage of the biliary system in benign and malignant diseases when the bile duct is inaccessible by conventional ERCP.
  • [MeSH-minor] Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / therapy. Female. Gallstones / therapy. Humans. Male. Middle Aged. Pancreatic Neoplasms / complications. Ultrasonography, Interventional

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086710.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tantau M, Pop T, Badea R, Spirchez Z, Moşteanu O, Tantau A: Intraductal ultrasonography for the assessment of preoperative biliary and pancreatic strictures. J Gastrointestin Liver Dis; 2008 Jun;17(2):217-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal ultrasonography for the assessment of preoperative biliary and pancreatic strictures.
  • Diseases of the biliary and pancreatic ducts are often difficult to diagnose.
  • Although transcutaneous ultrasonography, computer tomography and magnetic resonance greatly improved in performance, two major problems have not been completely solved yet: first, the differentiation of malignant and benign bile duct strictures, and, second, the assessment of the resectability of carcinomas underlying biliary strictures.
  • Ultrasound probes can be inserted through the working channel of the duodenoscope and passed selectively both into the biliary and pancreatic ducts.
  • The main clinical indication for intraductal ultrasonography of the biliary tract is obstructive jaundice, which requires assessment of bile duct strictures and local tumor staging.
  • Miniprobes can contribute to the differential diagnosis of strictures localized in the main pancreatic duct, and also to localizing small endocrine tumors.
  • [MeSH-major] Cholestasis / ultrasonography. Endosonography / methods. Pancreatic Diseases / ultrasonography. Pancreatic Ducts / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568147.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 25
  •  go-up   go-down


36. Agarwal B, Krishna NB, Labundy JL, Safdar R, Akduman EI: EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct. Gastrointest Endosc; 2008 Aug;68(2):237-42; quiz 334, 335
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct.
  • BACKGROUND: Incidental findings of an enlarged head of pancreas (HOP) or dilated pancreatic duct (PD) with or without a dilated common bile duct (CBD) on CT or magnetic resonance imaging (MRI), in patients without obstructive jaundice, raise suspicion for a pancreatic neoplasm, but their clinical significance has not been established.
  • OBJECTIVE: To determine the prevalence of pancreatic neoplasm in this patient group.
  • INTERVENTIONS: An EUS examination was performed by using a radial echoendoscopy followed by a linear echoendoscopy, if a focal pancreatic lesion was identified.
  • (1) The prevalence of pancreatic neoplasms and (2) performance characteristics of EUS-FNA for identifying malignant neoplasm, in this patient group.
  • RESULTS: In 110 study patients, the final diagnosis included adenocarcinoma (n = 7), pancreatic intraepithelial neoplasia (n = 1), neuroendocrine tumor (n = 1), tumor metastasis (n = 1), and benign cyst (n = 3).
  • The accuracy of EUS and EUS-FNA for diagnosing pancreatic neoplasm in these patients was 99.1%, with 88.8% sensitivity, 100% specificity, 99% negative predicative value, and 100% positive predictive value.
  • CONCLUSION: A pancreatic neoplasm is seen in a clinically significant number of patients with "enlarged HOP" or "dilated PD with or without a dilated CBD" but without obstructive jaundice.
  • EUS-FNA seems highly accurate for diagnosing pancreatic neoplasm in these patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle / methods. Diagnostic Imaging / methods. Endosonography / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Age Distribution. Aged. Cohort Studies. Common Bile Duct / pathology. Common Bile Duct / ultrasonography. Female. Humans. Immunohistochemistry. Incidence. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreatic Ducts / ultrasonography. Pancreatitis / diagnosis. Pancreatitis / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Sex Distribution. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2010 Jan;42(1):68-72 [20066593.001]
  • (PMID = 18423464.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Satoh K, Hamada S, Kanno A, Hirota M, Umino J, Ito H, Masamune A, Egawa S, Unno M, Shimosegawa T: Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2010 Jul;45(7):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.
  • BACKGROUND: To distinguish malignant from benign branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) still remains difficult.
  • Recently, we revealed that MSX2 was frequently expressed in pancreatic cancer and its expression was correlated with aggressive behavior of the cancer.
  • The aim of this study was to assess the involvement of MSX2 in IPMN development and whether its expression would differentiate malignant from benign IPMN.
  • The role of MSX2 in the pancreatic duct cell was assessed by the induced expression of MSX2 in a normal human pancreatic duct epithelial cell line (HPDE).
  • RESULTS: Malignant IPMN expressed significantly higher levels of MSX2 mRNA than benign IPMN lesions.
  • MSX2 protein expression was frequently found in borderline and malignant lesions (20/29, 68.9%), while its expression was seen in only one of 16 benign IPMN tissues.
  • CONCLUSIONS: Based on our results, MSX2 plays a pivotal role in the development of IPMN through growth stimulation of tumor cells, and its expression was identified as an independent predictive factor for malignancy of BD-IPMN.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Papillary / genetics. Homeodomain Proteins / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Aged. Cell Line. Cell Proliferation. Epithelial Cells / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Multivariate Analysis. Pancreatic Ducts / cytology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Predictive Value of Tests. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4222-6 [9766641.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2269-75 [16331618.001]
  • [Cites] Dev Biol. 1999 Jan 15;205(2):260-74 [9917362.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] Am J Pathol. 2008 Apr;172(4):926-39 [18349132.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2153-60 [11360199.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):662-3 [12399053.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15 [9951855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7482-6 [1977161.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):195-205 [15300013.001]
  • [Cites] Pancreas. 1996 May;12(4):362-8 [8740403.001]
  • [Cites] Development. 1996 Sep;122(9):2729-37 [8787747.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):768-74 [17516553.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Dev Biol. 1999 May 15;209(2):298-307 [10328922.001]
  • [Cites] Nature. 1991 Aug 1;352(6334):429-31 [1677742.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Int J Pancreatol. 1993 Oct;14(2):135-43 [8283077.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1379-84 [16105124.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7526-34 [17546050.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):51-6 [8099533.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jul 15;194(1):187-93 [7687426.001]
  • [Cites] Mod Pathol. 2007 Dec;20(12):1238-44 [17906614.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4 [14535994.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1763-70 [8669463.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Development. 1993 Feb;117(2):461-70 [8101167.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2137-46 [8668339.001]
  • (PMID = 20107842.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MSX2 protein; 0 / RNA, Messenger
  •  go-up   go-down


38. Ulla Rocha JL, Alvarez Sanchez MV, Paz Esquete J, Fernandez Salgado E, Alvarez Alvarez C, Vazquez Sanluis MJ, Ledo Barro L, Vazquez Astray E: Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP; 2007;8(2):191-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation.
  • CONTEXT: When assessing the bilio-pancreatic region, collating the findings of serum CA 19-9 values together with findings from various imaging tests--especially endoscopic ultrasonography--is not a simple issue in daily clinical practice.
  • Patients with previous attacks of acute pancreatitis and also those who presented with bile duct dilation or space-occupying lesions in image studies (US and CT) were excluded.
  • The results of EUS in the asymptomatic patients were: chronic pancreatitis in 7 patients, no pancreatic alterations in 3 patients, and renal cysts, choledocholithiasis, microlithiasis and liver cirrhosis in one patient, respectively.
  • CONCLUSIONS: When EUS was indicated for the asymptomatic elevation of CA 19-9, the main findings were benign diseases.
  • EUS was useful in studying patients with idiopathic abdominal pain and a slight elevation of CA 19-9 since it allowed us to detect chronic pancreatitis and even early adenocarcinoma of the pancreatic tail.
  • [MeSH-minor] Acute Disease. Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Humans. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356242.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


39. Shin SS, Armao DM, Shah M, Kim YH, Lee CH, Rubinas T, Brubaker LM, Semelka RC: Management of branch-duct intraductal papillary mucinous neoplasms of the pancreas: observation with MR imaging. Magn Reson Imaging; 2010 Dec;28(10):1440-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of branch-duct intraductal papillary mucinous neoplasms of the pancreas: observation with MR imaging.
  • PURPOSE: To evaluate the clinical outcomes of conservative management by observation with MRI of patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs).
  • On MRI, number of lesions, the maximum diameter of BD-IPMNs, lesion location, the presence of associated dilatation of main pancreatic duct (MPD), the presence of enhancing mural nodules within the lesion and the presence of interval change were retrospectively reviewed on initial and follow-up MR images in consensus by two radiologists.
  • There was no patient who had evidence of local aggressive growth of tumor or evidence of metastases to distant sites.
  • CONCLUSION: Our study suggests that branch-duct IPMNs without enhancing mural nodules are essentially benign and should be managed nonoperatively through observation by MRI.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Ductal / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20833500.001).
  • [ISSN] 1873-5894
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, Fujita Y, Uchiyama K, Yamaue H: Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg; 2009 Apr;144(4):345-9; discussion 349-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
  • Identification of predictive factors for differentiating IPMC from benign IPMNs would assist in providing appropriate treatment.
  • PATIENTS: Fifty-four patients with IPMN who underwent surgery; histologic examination showed benign adenomas in 29, carcinoma in situ in 14, and invasive carcinoma in 11 patients.
  • MAIN OUTCOME MEASURES: Clinical data, preoperative imaging findings, cytologic findings, tumor markers in serum and pancreatic juice, and overall survival.
  • RESULTS: Age of 70 years or older, presence of mural nodules, mural nodule size of 5 mm or larger, and carcinoembryonic antigen (CEA) level in pancreatic juice of 110 ng/mL or higher (as obtained by preoperative endoscopic retrograde pancreatography) were predictive of a malignant IPMN by univariate analysis, and a CEA level of 110 ng/mL or higher in pancreatic juice was identified as the only independent predictive factor for the malignant entity.
  • The presence of jaundice or body weight loss, main pancreatic duct type, presence of mural nodules, mural nodule size of 5 mm or larger, and CEA level in the pancreatic juice of 110 ng/mL or higher were all predictive of invasive IPMCs by univariate analysis.
  • CONCLUSION: Measurement of the CEA level in pancreatic juice should be considered in the diagnosis of IPMC.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380648.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Bandyopadhyay S, Basturk O, Coban I, Thirabanjasak D, Liang H, Altinel D, Adsay NV: Isolated solitary ducts (naked ducts) in adipose tissue: a specific but underappreciated finding of pancreatic adenocarcinoma and one of the potential reasons of understaging and high recurrence rate. Am J Surg Pathol; 2009 Mar;33(3):425-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated solitary ducts (naked ducts) in adipose tissue: a specific but underappreciated finding of pancreatic adenocarcinoma and one of the potential reasons of understaging and high recurrence rate.
  • The glandular units of invasive carcinoma are often well formed with well-polarized cells, appearing deceptively benign.
  • In this study, the frequency of ISDs was investigated in 105 pancreatic resections with ductal adenocarcinoma and 32 with chronic pancreatitis only.
  • ISD was detected in 50/105 (47.6%) of pancreatic resections for ductal adenocarcinoma, but not in any resections with chronic pancreatitis only (specificity 100%; sensitivity 47.6%).
  • A small subset of these units represented vascular invasion, in which the carcinoma cells epithelialized the vessel lining, transforming the vessel into a duct-like structure, virtually indistinguishable from normal ducts or PanINs.
  • ISDs were often located in histologic sections taken for the evaluation of the retroperitoneal margin and pancreatic-free surfaces where adipose tissue is more abundant.
  • In conclusion, ISD lying in adipose tissue unaccompanied by other elements, present in 47.6% of pancreatic resections when peripancreatic soft tissues away from the tumor are sampled, is a very specific finding for carcinoma that may be instrumental in the diagnosis and staging of carcinoma as well as margin evaluation.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pancreatitis / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092633.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


43. Alldinger I, Dittert D, Peiper M, Fusco A, Chiappetta G, Staub E, Lohr M, Jesnowski R, Baretton G, Ockert D, Saeger HD, Grützmann R, Pilarsky C: Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology; 2005;5(4-5):370-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer.
  • BACKGROUND: Pancreatic cancer is one of the leading causes of cancer-related death.
  • Using DNA gene expression analysis based on a custom made Affymetrix cancer array, we investigated the expression pattern of both primary and established pancreatic carcinoma cell lines.
  • METHODS: We analyzed the gene expression of 5 established pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-1, Capan-2 and HPAF II) and 5 primary isolates, 1 of them derived from benign pancreatic duct cells.
  • RESULTS: Out of 1,540 genes which were expressed in at least 3 experiments, we found 122 genes upregulated and 18 downregulated in tumor cell lines compared to benign cells with a fold change >3.
  • Several of the upregulated genes (like Prefoldin 5, ADAM9 and E-cadherin) have been associated with pancreatic cancer before.
  • The other differentially regulated genes, however, play a so far unknown role in the course of human pancreatic carcinoma.
  • By means of immunohistochemistry we could show that thymosin beta-10 (TMSB10), upregulated in tumor cell lines, is expressed in human pancreatic carcinoma, but not in non-neoplastic pancreatic tissue, suggesting a role for TMSB10 in the carcinogenesis of pancreatic carcinoma.
  • CONCLUSION: Using gene expression profiling of pancreatic cell lines we were able to identify genes differentially expressed in pancreatic adenocarcinoma, which might contribute to pancreatic cancer development.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Down-Regulation. Gene Expression Profiling. Pancreatic Neoplasms / genetics. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Male. Middle Aged. Pancreas / metabolism. Thymosin / genetics. Thymosin / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15983444.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 61512-21-8 / Thymosin; 87397-91-9 / thymosin beta(10)
  •  go-up   go-down


44. Takaori K, Hruban RH, Maitra A, Tanigawa N: Current topics on precursors to pancreatic cancer. Adv Med Sci; 2006;51:23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current topics on precursors to pancreatic cancer.
  • Prognosis of invasive pancreatic ductal adenocarcinoma is bleak and the vast majority of patients with pancreatic cancer die of their disease.
  • The detection and treatment of the non-invasive precursor lesions of pancreatic cancer offer the opportunity to cure this devastating disease and therefore great efforts are being made to identify the precursors to pancreatic cancer.
  • Mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic intraepithelial neoplasias (PanINs) all harbor varying degrees of dysplasia and stepwise accumulation of genetic alterations, suggesting progression of these lesions from benign toward malignant neoplasms.
  • IPMNs are recently established clinical entity with characteristic features of mucin hypersecretion and duct dilatation.
  • Some IPMNs are associated with invasive carcinoma and IPMNs are recognized precursors to pancreatic cancer.
  • PanINs are microscopic proliferative lesions arising from any parts of the pancreatic duct system.
  • Low grade PanINs are commonly found in pancreatic ducts of elder individuals, while high grade PanINs, previously called carcinoma in situ/severe ductal dysplasia, may eventually give rise to invasive pancreatic cancer.
  • Further investigation of these precursor lesions is expected to reduce the mortality from pancreatic cancer.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Disease Progression. Humans. Models, Biological. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357272.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 81
  •  go-up   go-down


45. Nakao A, Fernández-Cruz L: Pancreatic head resection with segmental duodenectomy: safety and long-term results. Ann Surg; 2007 Dec;246(6):923-8; discussion 929-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic head resection with segmental duodenectomy: safety and long-term results.
  • OBJECTIVE: To evaluate the usefulness and long-term results with pancreatic head resection with segmental duodenectomy (PHRSD; Nakao's technique) in patients with branch-duct type intraductal papillary mucinous neoplasms (IPMNs).
  • Recently, organ-preserving pancreatic resections for benign and noninvasive IPMN located in the head of the pancreas have been described.
  • We have PHRSD in which the pancreatic head can be completely resected and the major portion of the duodenum can be preserved by this procedure.
  • Mean maximal diameter of the cystic lesion was 26.4 +/- 5.3 mm (range, 20-33 mm) and mean diameter of the main pancreatic duct was 3.3 +/- 0.5 mm (range, 3.0-4.0 mm).
  • In the latter group were included 32 patients with branch-duct type of IPMN operated during the same time period that patients with PHRSD.
  • Pancreatic fistula occurred in 10% and 13% with types (alimentary tract reconstruction) A and B, respectively.
  • The overall incidence of pancreatic fistula was higher after PPPD than after PHRSD; the difference was not statistically significant.
  • In contrast, pancreatic fistulas after PPPD were grade A in 78% of cases and grade B in 22% (clinically relevant fistula).
  • Endocrine pancreatic function, measured by fasting blood glucose levels and HbA1, levels was unchanged in 94.28% of patients, in the PHRSD group, and in 87.87% in the PPPD group.
  • The 5-year survival rate was 100% in patients with benign IPMN and 42% in patients with invasive IPMN.
  • CONCLUSION: PHRSD is a safe and reasonable technique appropriate for selected patients with branch-duct IPMN.
  • The major advantages of PHRSD are promising long-term results in terms of pancreatic function (exocrine and endocrine) with important consequences in elderly patients.
  • Long-term outcome was satisfactory without tumor recurrence in noninvasive carcinoma.
  • PHRSD should therefore be considered as an adequate operation as an organ-preserving pancreatic resection for branch-duct type of IPMN located at the head of the pancreas.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Sep;248(3):498-9 [18791375.001]
  • (PMID = 18043093.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


46. Nagaike K, Chijiiwa K, Hiyoshi M, Ohuchida J, Kataoka H: Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule. Int J Clin Oncol; 2007 Oct;12(5):388-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule.
  • Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized entity representing a spectrum of benign and malignant neoplasms of the pancreas.
  • Preoperative distinction between benign and malignant IPMNs remains difficult.
  • Reported predictive factors for malignancy are size of the main pancreatic duct, cystic neoplasm, and mural nodule.
  • We report herein the case of a 50-year-old woman in whom a large mural nodule (30 mm) in the dilated main pancreatic duct (16 mm in diameter) was detected by ultrasonography, computed tomography, and endoscopic retrograde cholangiopancreatography.
  • Because the large mural nodule and dilatation of the main pancreatic duct were also detected by endoscopic ultrasonography (EUS) and intraductal ultrasonography (IDUS), the main-duct IPMN was considered to have malignant potential.
  • The resected intraductal tumor appeared polypoid with a broad stalk and comprised a proliferation of mucin-containing columnar epithelial cells with papillary structures without malignant features.
  • The size of the mural nodule and the final diagnosis in this case suggest that the introduction of a novel molecular-biological approach might be necessary for the precise preoperative diagnosis of main-duct IPMN and adequate surgical treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):223-9 [10231655.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • (PMID = 17929124.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Orihara M, Kuroki M, Hiramoto K, Shohji H, Matsumura Y, Kikuchi Y, Hirakawa H, Maeda K: A case of serous cystic tumor, which recurred with severe acute pancreatitis. Nihon Shokakibyo Gakkai Zasshi; 2010 Jun;107(6):923-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of serous cystic tumor, which recurred with severe acute pancreatitis.
  • A 76-year-old woman with serous cystic tumor (SCT) was admitted to our hospital with abdominal pain and was given a diagnosis of severe acute pancreatitis.
  • We supposed that the growth of the SCT after hemorrhage compressed the main pancreatic duct and caused severe acute pancreatitis.
  • SCT is benign, and there are no standard treatments.
  • [MeSH-major] Cystadenoma, Serous / complications. Pancreatic Neoplasms / complications. Pancreatitis / etiology
  • [MeSH-minor] Acute Disease. Aged. Female. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530929.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Tanno S, Sasajima J, Koizumi K, Yanagawa N, Nakano Y, Osanai M, Mizukami Y, Fujii T, Obara T, Okumura T, Kohgo Y: Tumor doubling time in two cases of main duct intraductal papillary-mucinous neoplasms of the pancreas. Hepatogastroenterology; 2009 Sep-Oct;56(94-95):1545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor doubling time in two cases of main duct intraductal papillary-mucinous neoplasms of the pancreas.
  • The present study reports the growth rate in two cases of main duct pancreatic intraductal papillary-mucinous neoplasms (MD-IPMNs) demonstrating significant changes over several years' observation.
  • The first patient was a 74-year-old woman with an incidental finding of diffuse dilatation of the main pancreatic duct (MPD).
  • The tumor volume doubling time of these MD-IPMNs was 141 and 304 days in patient 1 and 2, respectively, with a mean of 222.5 days.
  • The present reports demonstrate the ability of benign MD-IPMNs to grow at a significant rate, supporting the current consensus guidelines that MD-IPMNs require surgical resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Pancreatic Ductal / pathology. Female. Humans. Pancreatic Ducts. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950827.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


49. Alvaro D: Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol; 2009 May;25(3):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To discuss recent studies proposing new markers in serum or bile for the diagnosis and prognosis of cholangiocarcinoma (CCA), which could help in the differential diagnosis between malignant and benign biliary disorders or for the surveillance of disorders at risk, including primitive sclerosing cholangitis.
  • As far as bile is concerned, the ratio of pancreatic elastase/amylase, mucin-4, minichromosome maintenance replication protein and insulin-like growth factor 1 have been explored, with the insulin-like growth factor 1 biliary concentration capable of completely discriminating CCA from benign biliary disorders and pancreatic cancer.
  • [MeSH-major] Bile / chemistry. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Biomarkers, Tumor / metabolism. Cholangiocarcinoma / metabolism. Cytokines / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396965.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines
  • [Number-of-references] 33
  •  go-up   go-down


50. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


51. Ichimura T, Kondo S, Okamura K, Tanaka E, Hirano S: Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case. Hepatogastroenterology; 2010 Jan-Feb;57(97):8-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case.
  • For patients with benign or low malignant diseases of the pancreas, several organ-preserving surgical techniques of pancreatectomy have been presented for localized lesions.
  • We herein report a patient with widespread intraductal papillary mucinous neoplasm treated successfully with total parenchymal pancreatectomy.
  • A 73-year-old man was diagnosed as main duct intraductal papillary mucinous neoplasm.
  • A papillary tumor was located in the body of the pancreas, and intraepithelial spreading reached almost the end of the pancreas tail and nearly over the midpoint of the pancreas head.
  • We performed total parenchymal pancreatectomy, an initial surgical procedure in which almost all parenchyma of the pancreas was resected but the duodenum, the common bile duct and the spleen were preserved and no reconstruction was needed.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Common Bile Duct. Duodenum. Humans. Male. Spleen

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422863.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Ge C, Luo X, Chen X, Guo K: Enucleation of pancreatic cystadenomas. J Gastrointest Surg; 2010 Jan;14(1):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enucleation of pancreatic cystadenomas.
  • BACKGROUND: Optimal surgical treatment of pancreatic cystadenomas is controversial due to the rarity of the tumors and paucity of studies regarding long-term outcomes.
  • This is especially true for large pancreatic cystadenomas.
  • The objective of this study was to determine the safety and effectiveness of treating pancreatic cystadenomas by enucleation.
  • METHODS: Eleven cases of pancreatic mucinous or serous cystadenomas were selected for enucleation according to the following criteria:.
  • (1) the benign nature of the tumors was ascertained preoperatively and intraoperatively, (2) small tumors or larger tumors no more than 6 cm in diameter growing outwardly with small tumor beds, and (3) the main pancreatic duct was not in jeopardy of damage by enucleation.
  • The patients' demographics, tumor features, morbidity, and follow-up results were retrospectively reviewed and analyzed.
  • All cases were followed up from 23 to 67 months, which revealed no neoplasm recurrence or new onset of diabetes mellitus; one patient developed a pseudocyst in the body 30 months after enucleation.
  • CONCLUSIONS: It is safe and effective to perform enucleation for well-selected benign pancreatic cystadenomas even if the tumor size is as large as 6 cm, and the endocrine or exocrine function of the pancreas is maintained as much as possible.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Apr;205(4):393-8 [3566376.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):269-80 [7673858.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(2):167-70 [17384908.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1681-6 [14571816.001]
  • [Cites] Baillieres Clin Gastroenterol. 1996 Dec;10(4):645-71 [9113316.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):327-31 [16504877.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):264-75 [16498592.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Jan;24(1):121-4 [10679598.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):132-9 [1546898.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):890-7 [14592663.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] Am Surg. 2004 Feb;70(2):106-12; discussion 113 [15011911.001]
  • [Cites] J Gastrointest Surg. 2007 Jun;11(6):726-9 [17726774.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • (PMID = 19779948.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol; 2008 Feb;15(2):583-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Analysis of the areas under the receiver operator characteristic (ROC) curves clearly showed better discrimination between intrahepatic cholangiocarcinoma and benign liver diseases for CYFRA 21-1 than for CEA or CA 19-9.
  • The serum CYFRA21-1 concentration was related to tumor stage, since the CYFRA21-1 concentrations varied according to tumor size, vascular invasion, and number of tumors.
  • On multivariate analysis, a high concentration of CYFRA21-1, nodal metastases, and a microscopic resection margin involvement were independent prognostic factors associated with both tumor recurrence and postoperative death.
  • CONCLUSIONS: A high serum CYFRA21-1 concentration is associated with tumor progression and poor postoperative outcomes in patients with intrahepatic cholangiocarcinoma.
  • [MeSH-major] Antigens, Neoplasm / blood. Bile Duct Neoplasms / blood. Bile Ducts, Intrahepatic. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. Keratins / blood
  • [MeSH-minor] Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Disease-Free Survival. Female. Humans. Keratin-19. Lymphatic Metastasis. Male. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. ROC Curve. Sensitivity and Specificity


54. Bohnacker S, Seitz U, Nguyen D, Thonke F, Seewald S, deWeerth A, Ponnudurai R, Omar S, Soehendra N: Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. Gastrointest Endosc; 2005 Oct;62(4):551-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth.
  • BACKGROUND: Endoscopic papillectomy of benign papillary tumor is still not widely practiced.
  • This prospective study evaluates endoscopic papillectomy for treatment of benign papillary tumors without and with intraductal growth.
  • A 7F stent was placed in the pancreatic duct.
  • Median tumor size was 2 cm (range 0.5-6 cm) with one session (range 1-8) required for removal.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Sphincterotomy, Endoscopic / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2006 Apr;63(4):737; author reply 737-8 [16564901.001]
  • (PMID = 16185970.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Stewart GD, Skipworth RJ, Pennington CJ, Lowrie AG, Deans DA, Edwards DR, Habib FK, Riddick AC, Fearon KC, Ross JA: Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. Br J Cancer; 2008 Jul 08;99(1):126-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate dermcidin expression in cell lines following simulation of tumour microenvironmental conditions and in a range of primary tumours.
  • Tumour tissues were collected from patients with oesophageal (28 samples), gastric (20), pancreatic (five), bile duct (one) and prostatic (52) carcinomas as well as 30 benign tissue samples, for assessment of dermcidin mRNA levels using real-time PCR.
  • Dermcidin expression was assessed in prostatic and pancreatic cancer cell lines, with and without induction of hypoxia or oxidative stress.
  • None of the primary prostate tissue, benign or malignant, expressed dermcidin mRNA.
  • However, three (60%) of the pancreatic cancer samples and the single cholangiocarcinoma specimen had moderate/high levels of dermcidin expression.
  • Of the two pancreatic cancer cell lines, one expressed dermcidin moderately but neither showed a response to hypoxia or oxidative stress.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Humans. Hypoxia / physiopathology. Oxidative Stress / physiology. Peptides. Polymerase Chain Reaction. RNA, Messenger / biosynthesis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Immunol. 2001 Dec;2(12):1133-7 [11694882.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 May;11(3):208-13 [18403914.001]
  • [Cites] BJU Int. 2003 Mar;91(4):315-23; discussion 323-4 [12603403.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):123-9 [12672042.001]
  • [Cites] J Cell Physiol. 2003 Jun;195(3):356-72 [12704645.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10931-6 [12953101.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):437-47 [15170446.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):165-9 [15270886.001]
  • [Cites] Am J Med. 1980 Oct;69(4):491-7 [7424938.001]
  • [Cites] Nature. 1996 Feb 22;379(6567):739-42 [8602222.001]
  • [Cites] Br J Cancer. 1997;76(5):606-13 [9303359.001]
  • [Cites] Br J Cancer. 1997;76(8):1035-40 [9376263.001]
  • [Cites] J Neurosci. 1998 Sep 15;18(18):7047-60 [9736629.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):731-6 [16495932.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1663-71 [16685272.001]
  • [Cites] Prostate. 2007 Sep 1;67(12):1308-17 [17626247.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4984-92 [17785548.001]
  • [Cites] Exp Neurol. 2002 Sep;177(1):32-9 [12429208.001]
  • (PMID = 18594538.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100250; United Kingdom / Chief Scientist Office / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Peptides; 0 / RNA, Messenger; 0 / dermcidin
  • [Other-IDs] NLM/ PMC2453008
  •  go-up   go-down


56. Jang JY, Kim SW, Ahn YJ, Yoon YS, Choi MG, Lee KU, Han JK, Kim WH, Lee YJ, Kim SC, Han DJ, Kim YI, Choi SH, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee KB, Kim YC, Lee KS, Kim MW, Kim HJ, Kim HJ, Park YH: Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol; 2005 Feb;12(2):124-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery?
  • A total of 124 patients underwent pancreatoduodenectomy, 42 underwent distal pancreatectomy, 17 underwent total pancreatectomy, and 25 underwent limited pancreatic resection.
  • There were 128 benign cases (adenoma, n = 62; borderline, n = 66) and 80 malignant cases (noninvasive, n = 29; invasive, n = 51).
  • A significant difference in 5-year survival was observed between the benign and malignant groups (92.6% vs. 65.3%; P = .006).
  • Of the six factors (age, location, duct dilatation, mural nodule, main duct type, and tumor size) that showed statistical differences by univariate analysis between the benign and malignant groups, three were significant by multivariate analysis--namely, mural nodule (P = .009), tumor size (P = .023), and a dilated duct size (P = .010).
  • CONCLUSIONS: A significant proportion of IPMTs are malignant, although the overall prognosis of IPMT is superior to that of ordinary pancreatic cancer.
  • Radical surgery is recommended for IPMT with the predictors of malignancy: mural nodule, tumor size (> or =30 mm), and dilated duct size (> or =12 mm).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreatectomy. Pancreaticoduodenectomy. Preoperative Care. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):98-9 [15827786.001]
  • (PMID = 15827792.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


57. Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A, Ruszniewski P: Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas; 2005 Jul;31(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?
  • OBJECTIVES: Pancreatic endocrine tumors (PETs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are rare diseases of the pancreas.
  • RESULTS: Preoperative diagnosis was unspecified pancreatic tumor (n = 1), IPMN (n = 2), and association of PET and IPMN (n = 3).
  • IPMN involved the main pancreatic duct in 4 patients and was classified as benign (n = 4), borderline (n = 1), or malignant noninvasive (n = 1).
  • CONCLUSION: This study describes a new aspect of endocrine-exocrine pancreatic neoplasm association.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968252.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 9007-92-5 / Glucagon
  •  go-up   go-down


58. Nilsson HO, Stenram U, Ihse I, Wadstrom T: Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J Gastroenterol; 2006 May 21;12(19):3038-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients.
  • AIM: To determine whether gastric and enteric Helicobacter species are associated with pancreatic cancer.
  • METHODS: Patients with exocrine pancreatic cancer (n = 40), neuroendocrine cancer (n = 14), multiple endocrine neoplasia type 1 (n = 8), and chronic pancreatitis (n = 5) were studied.
  • Other benign pancreatic diseases (n = 10) and specimens of normal pancreas (n = 7) were included as controls.
  • Pancreatic tissue specimens were analyzed by Helicobacter-specific PCR-assay and products were characterized by denaturing gradient electrophoresis and DNA-sequencing.
  • From a subset of the pancreatic cancer patients, gastric and/or duodenal tissue as well as gallbladder and ductus choledochus tissue were analyzed.
  • Stomach and duodenum samples were investigated to analyze whether a gastric helicobacter might disseminate to the pancreas in pancreatic cancer patients.
  • Pancreatic specimens were analyzed by Bacteroides-specific PCR for detecting the translocation of indigenous gut microbes to the diseased pancreas.
  • RESULTS: Helicobacter DNA was detected in pancreas (tumor and/or surrounding tissue) of 75% of patients with exocrine cancer, 57% of patients with neuroendocrine cancer, 38% of patients with multiple endocrine neoplasia, and 60% of patients with chronic pancreatitis.
  • All samples from other benign pancreatic diseases and normal pancreas were negative.
  • Bacteroides PCR-assay was negative for all pancreatic samples.
  • CONCLUSION: Helicobacter DNA commonly detected in pancreatic cancer suggests a possible role of the emerging pathogens in the development of chronic pancreatitis and pancreatic cancer.
  • [MeSH-major] Carcinoma, Neuroendocrine / microbiology. DNA, Ribosomal / analysis. Duodenum / chemistry. Helicobacter / genetics. Multiple Endocrine Neoplasia Type 1 / microbiology. Pancreas / chemistry. Pancreatic Neoplasms / microbiology. Stomach / chemistry
  • [MeSH-minor] Adult. Aged. Bacteroides / genetics. Bacteroides / physiology. Case-Control Studies. Common Bile Duct / chemistry. Common Bile Duct / microbiology. Female. Gallbladder / chemistry. Gallbladder / microbiology. Helicobacter Infections / complications. Helicobacter Infections / genetics. Humans. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2002 Jul;93(7):842-7 [12149151.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1946-53 [12404289.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Clin Infect Dis. 2003 Feb 1;36(3):349-54 [12539077.001]
  • [Cites] J Med Microbiol. 2003 Sep;52(Pt 9):765-71 [12909652.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1171-4 [14560149.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5615-8 [14662950.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Comp Med. 2004 Apr;54(2):128-58 [15134359.001]
  • [Cites] Gut. 2004 Jun;53(6):860-4 [15138214.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966.001]
  • [Cites] Helicobacter. 2004 Oct;9(5):460-8 [15361086.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):375-82 [8347787.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1222-7 [8040890.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):16-9 [9428370.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):1-9 [9445103.001]
  • [Cites] Br Med Bull. 1998;54(1):71-8 [9604432.001]
  • [Cites] Science. 2004 Nov 5;306(5698):966-8 [15528423.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):304-12 [15685542.001]
  • [Cites] Gut. 2005 Mar;54(3):396-401 [15710989.001]
  • [Cites] Gut. 2000 Mar;46(3):410-4 [10673306.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1072-6 [10698999.001]
  • [Cites] Curr Microbiol. 2000 Sep;41(3):161-6 [10915200.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1431-9 [11013355.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):323-4 [11246512.001]
  • [Cites] Cancer Invest. 2001;19(1):65-75 [11291558.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):937-41 [11416115.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):632-3 [11959898.001]
  • [Cites] Pancreatology. 2002;2(4):386-95 [12138227.001]
  • (PMID = 16718784.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Ribosomal
  • [Other-IDs] NLM/ PMC4124378
  •  go-up   go-down


59. Horiguchi A, Miyakawa S, Ishihara S, Ito M, Asano Y, Furusawa K, Shimizu T, Yamamoto T: Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):792-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors.
  • To apply duodenum-preserving pancreatic head resection (DPPHR) as radical procedure for benign or low-grade malignant tumors, it needs the reconciliation of complete pancreatic head resection and preservation of the bile duct and peripancreatic vessels.
  • Several modifications have been introduced and applied to remove these lesions, however, the techniques have not been made clear in the management of the peripancreatic vessels and the bile duct.
  • The long-term outcomes of the DPPHR have been reported as extremely rare in comparison with pylorus preserving pancreatoduodenectomy (PPPD) in these pancreatic head tumors.
  • Therefore, we modified the DPPHR to include a complete resection of the pancreatic head and the preservation of both anterior and posterior arterial arcades.
  • The bile duct is covered by the pancreatic parenchyma in various ways.
  • The techniques of the preservation of the bile duct are also introduced.
  • We performed 21 DPPHRs and 19 PPPDs in the patients with benign or low-grade malignant pancreatic head tumor.
  • The DPPHR should be favored over the PPPD in benign or low-grade malignant tumors of the head of the pancreas if there is no compromise with oncologic radicality.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Angiography. Female. Follow-Up Studies. Humans. Laparotomy. Length of Stay. Male. Middle Aged. Neoplasm Staging. Pancreas / blood supply. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894017.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL: S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol; 2010 Sep;41(9):1210-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
  • Histopathologic distinction between benign and malignant bile duct epithelial lesions on endoscopic biopsies can be extremely challenging because of limited material, crush artifact, and compounding inflammatory and/or reactive changes particularly after stent placement.
  • In this study, a total of 72 endoscopic bile duct biopsies, including 40 adenocarcinomas and 32 benign cases, were immunohistochemically examined for the expression of S100P, von Hippel-Lindau gene product (pVHL), and IMP3 to evaluate their diagnostic value.
  • All 32 benign biopsies were completely negative for IMP3 with the exception of 2 cases with focal dysplasia where focal immunoreactivity was observed.
  • Thirty benign biopsies (93.8%) were positive for pVHL with a diffuse staining pattern observed in 28 cases (93.3%).
  • Eight benign biopsies (25%) showed focal S100P positivity.
  • Twenty-two benign biopsies (68.8%) displayed a S100P-/IMP3-/pVHL+ staining pattern.
  • In conclusion, an immunohistochemical panel consisting of S100P, pVHL, and IMP3 can be helpful in distinguishing adenocarcinoma from reactive epithelial changes on challenging bile duct biopsies.
  • The findings of focal S100P and/or IMP3 expression with reciprocal loss of pVHL immunoreactivity in a few benign biopsies suggest a use of these markers in the detection of early epithelial dysplasia that may be beyond histologic recognition.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / analysis. Nuclear Proteins / analysis. RNA-Binding Proteins / analysis. Von Hippel-Lindau Tumor Suppressor Protein / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / diagnosis. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / chemistry. Pancreatic Neoplasms / diagnosis. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Hum Pathol. 2011 Sep;42(9):1368; author reply 1368-9 [21704356.001]
  • (PMID = 20382408.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / IMP3 protein, human; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 0 / S100PBP protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


61. Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB: Intraoperative ultrasound of the pancreas. Ultrasound Q; 2009 Mar;25(1):39-48; quiz 48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pictorial essay will review common benign and malignant pancreatic processes including the following: pancreatic ductal adenocarcinoma, pancreatitis, endocrine tumors, mucinous cystic neoplasm, intraductal papillary mucinous neoplasm, serous cystadenoma, and solid pseudopapillary tumor.
  • (1) identification of insulinoma(s) which are not detectable preoperatively, (2) identification of the pancreatic duct to determine dissection planes for chronic pancreatitis surgery (eg, Puestow procedure) and for tumor resection, and (3) staging purposes for malignant disease.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Diseases / surgery. Pancreatic Diseases / ultrasonography. Surgery, Computer-Assisted / methods. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276960.001).
  • [ISSN] 1536-0253
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


62. Lehwald N, Cupisti K, Baldus SE, Kröpil P, Schulte Am Esch J 2nd, Eisenberger CF, Knoefel WT: Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series. J Med Case Rep; 2010;4:402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series.
  • INTRODUCTION: The standard operation for carcinoma of the pancreatic head is a partial pancreaticoduodenectomy.
  • Pathology revealed a benign multicystic mesothelioma.
  • Endoscopic retrograde cholangiopancreatographic examination and a computed tomography scan showed a stenosis of the distal bile duct secondary to a mass in the head of the pancreas and duodenum.
  • Benign multicystic mesothelioma is a very rare tumor that originates from the peritoneum.
  • Although it demonstrates a benign clinical behaviour, it frequently recurs after resection.
  • Adenomyoma of the bile duct or ampullary region is a very unusual, benign, localized lesion characterized by adenomyomatous hyperplasia.
  • Undifferentiated carcinoma, sarcomatoid variant, is an aggressive tumor and is characterized by spindle cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):530-6 [12808057.001]
  • [Cites] Surg Today. 2008;38(1):85-9 [18085373.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Pancreas. 2005 Oct;31(3):291-2 [16163064.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):547-50 [7550871.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Am J Obstet Gynecol. 1983 Feb 1;145(3):355-9 [6824025.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • (PMID = 21143956.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016302
  •  go-up   go-down


63. Casadei R, Ricci C, Rega D, D'Ambra M, Pezzilli R, Tomassetti P, Campana D, Nori F, Minni F: Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas; 2010 Aug;39(6):825-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.
  • OBJECTIVE: Pancreatic endocrine tumors (PETs) are usually small, benign or low-grade malignant, and surgery should preserve the pancreatic parenchyma as much as possible.
  • METHODS: Of 82 patients having PETs, 46 with tumor less than 4 cm in diameter, without distant metastases and with R0 resection by final pathologic examination, were included in this study.
  • Enucleation was performed when the tumor did not involve the main pancreatic duct and in the absence of peripancreatic lymphadenopathy (group A); a typical resection was carried out in all other cases (group B).
  • The 2 groups were compared regarding postoperative mortality and morbidity, pancreatic fistula, postoperative hospital stay, reoperation, World Health Organization classification, TNM stage, recurrence, and long-term survival.
  • Postoperative and long-term results were similar in the 2 groups, whereas World Health Organization classification was significantly different; enucleation was performed more frequently than typical R0 resection in benign tumors (P = 0.009).
  • CONCLUSIONS: Enucleation should be reserved for patients having benign PETs less than 4 cm in diameter and far from the main pancreatic duct.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome. World Health Organization

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431423.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Itoi T, Neuhaus H, Chen YK: Diagnostic value of image-enhanced video cholangiopancreatoscopy. Gastrointest Endosc Clin N Am; 2009 Oct;19(4):557-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilot studies suggest that chromoendocholangioscopy using methylene blue or cholangioscopy using AFI can distinguish benign from malignant bile duct lesions.
  • In patients with main-duct-type intraductal papillary mucinous neoplasm, peroral pancreatoscopy can be used to determine extent of tumor involvement.
  • Although many technical hurdles still need to be overcome, image-enhanced cholangiopancratoscopy appears to be a promising modality to improve diagnostic accuracy of pancreatobiliary diseases, particularly in distinguishing benign from malignant lesions.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Cholangiopancreatography, Endoscopic Retrograde / instrumentation. Image Enhancement. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Humans. Pancreatic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917461.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


65. Katayama M, Funakoshi A, Sumii T, Sanzen N, Sekiguchi K: Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas. Cancer Lett; 2005 Jul 8;225(1):167-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas.
  • The G2F level in pancreatic ductal cell adenocarcinoma patients with liver metastases was markedly elevated, but that in patients without liver metastases was not significantly elevated.
  • The G2F levels in patients with benign pancreatic tumours (pancreatic cysts and intraductal papillary mucinous tumours) were similar to that in healthy volunteers.
  • Interestingly, a significant increase in circulating G2F/G1F ratio was observed in patients with bile duct and gallbladder carcinoma, as well as in those with metastatic pancreatic ductal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Cell Adhesion Molecules / blood. Laminin / blood. Liver Neoplasms / secondary. Neoplasm Metastasis. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922869.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / kalinin
  •  go-up   go-down


66. Clarke T, Matsuoka L, Jabbour N, Mateo R, Genyk Y, Selby R, Gagandeep S: Gallbladder mass with a carbohydrate antigen 19-9 level in the thousands: malignant or benign pathology? Report of a case. Surg Today; 2007;37(4):342-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder mass with a carbohydrate antigen 19-9 level in the thousands: malignant or benign pathology? Report of a case.
  • Tumor markers such as carbohydrate antigen 19-9 (CA 19-9) are commonly measured in the serum of patients with suspected pancreaticobiliary malignancies.
  • Moderate elevations of CA 19-9 may be seen in benign disease, but levels in the thousands are indicative of malignancy.
  • The patient underwent cholecystectomy and excision of a common bile duct stricture, with hepaticojejunostomy and liver biopsy.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Cholecystitis / blood. Granuloma / blood. Xanthomatosis / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1255-8 [14571712.001]
  • [Cites] Eur Radiol. 2004 Mar;14 (3):440-6 [12904879.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] Am J Gastroenterol. 1994 Apr;89(4):628-30 [8147372.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):204-10 [15275874.001]
  • (PMID = 17387571.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


67. Chang S, Lim JH, Choi D, Kim SK, Lee WJ: Differentiation of ampullary tumor from benign papillary stricture by thin-section multidetector CT. Abdom Imaging; 2008 Jul-Aug;33(4):457-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of ampullary tumor from benign papillary stricture by thin-section multidetector CT.
  • The objective of this paper was to determine the criteria for differentiation of ampullary tumor from benign papillary stricture using thin-section multidetector CT images.
  • Multidetector CT images with 2.5 mm slice-thickness in 57 consecutive patients (24 with ampulla of Vater tumor and 33 with benign papillary stricture) with extrahepatic duct dilatation due to ampullary obstruction were reviewed retrospectively.
  • The papilla/papillary mass was evaluated regarding size, homogeneity of enhancement, attenuation value, and the diameters of extrahepatic duct and main pancreatic duct were measured.
  • The measurability, enhancement pattern, the attenuation value of papilla/papillary mass on portal venous phase, and the maximum diameters of extrahepatic duct and main pancreatic duct were different between two groups.
  • Multiple logistic regression analysis showed the papilla/papillary mass size was the only independently differentiating variable of ampullary tumor from benign stricture (P = 0.016) with an odds ratio of 2.424 (95% confidence interval, 1.179-4.903).
  • Ampullary tumor and benign papillary stricture could be effectively differentiated by thin-section multidetector CT based on papilla/papillary mass size.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Diseases / radiography. Common Bile Duct Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712590.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Cavallini M, Cecera A, Ciardi A, Caterino S, Ziparo V: Small periampullary duodenal gastrointestinal stromal tumor treated by local excision: report of a case. Tumori; 2005 May-Jun;91(3):264-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small periampullary duodenal gastrointestinal stromal tumor treated by local excision: report of a case.
  • Since no definitive clinical criteria have been established to differentiate malignant from benign mesenchymal tumors, preoperative cytology was not available and surgical removal of the 3.5 cm tumor was feasible, the patient was treated conservatively.
  • The morbidity and mortality rates of the more radical and invasive duodenopancreatectomy, in particular when dealing with a soft pancreatic stump with a narrow pancreatic duct, are, in our opinion, too high for a potentially benign disease when the more conservative procedure is feasible.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206653.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Chen B, Dong JQ, Chen YJ, Wang JM, Tian J, Wang CB, Zou SQ: Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):402-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (b) obtain 2-D biliary maps with high reproducibility and resolution; and (c) identify protein patterns present in 2-D biliary maps for potential tumor biomarker discovery, with the intention of distinguishing malignant from benign causes of bile duct obstruction.
  • METHODS: Bile fluid samples were obtained from two patients suffering from malignant and benign bile tract obstruction (one patient with cholangiocarcinoma as the experimental case, the other with cholelithiasis as control).
  • [MeSH-minor] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / metabolism. Humans. Hydrogen-Ion Concentration. Isoelectric Focusing / methods. Peptide Mapping. Proteome. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690038.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


70. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology; 2007 Jul;133(1):72-9; quiz 309-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection.
  • BACKGROUND & AIMS: Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in branch ducts are thought to be less aggressive than their main-duct counterparts, and guidelines for their conservative management were recently proposed.
  • This study describes the combined experience of 2 tertiary centers with branch-duct IPMNs aiming to validate these recommendations.
  • METHODS: A review of 145 patients with resected, pathologically confirmed, branch-duct IPMNs between 1990 and 2005 was conducted.
  • Median age was similar between benign and malignant subgroups (66 vs 67.5 years, respectively).
  • Jaundice was more frequent in patients with cancer (12.5% vs 1.8%, respectively, P = .022) and abdominal pain in patients with benign tumors (45% vs 25%, respectively, P = .025).
  • Findings associated with malignancy were the presence of a thick wall (P < .001), nodules (P < .001), and tumor diameter >or=30 mm (P < .001).
  • After a mean follow-up of 45 months, the 5-year disease-specific survival for branch-duct IPMNs with noninvasive neoplasms was 100% and, for invasive cancer, was 63%.
  • CONCLUSIONS: This large cohort of resected branch-duct IPMNs shows that cancer is present in 22% of cases and validates the recent guidelines that indicate absence of malignancy in tumors <30 mm, without symptoms or mural nodules.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Practice Guidelines as Topic / standards. Survival Analysis


71. Yaman B, Nart D, Yilmaz F, Coker A, Zeytunlu M, Kilic M: Biliary intraductal papillary mucinous neoplasia: three case reports. Virchows Arch; 2009 May;454(5):589-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary intraductal papillary mucinous neoplasia: three case reports.
  • Intraductal-growing type is an entity described in recent years as mucin-producing intrahepatic cholangiocarcinoma or intrahepatic (biliary) intraductal papillary mucinous neoplasia (b-IPMN).
  • b-IPMN is classified as adenoma, borderline tumor, carcinoma in situ, and carcinoma, from benign to malignant.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Papillary / pathology. Cholangiocarcinoma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Hepatitis B / complications. Hepatitis B / surgery. Humans. Immunoenzyme Techniques. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Liver Transplantation. Male. Middle Aged. Mucin 5AC / metabolism. Mucin-1 / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2007 Aug;39(4):413-8 [17676483.001]
  • [Cites] Histol Histopathol. 2008 Jan;23 (1):41-50 [17952856.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):902-10 [14562286.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] Pancreas. 2007 Nov;35(4):348-52 [18090241.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Lab Invest. 2004 May;84(5):629-38 [15048136.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1562-6 [2538218.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):34-8 [17240305.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1570-2 [17922173.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] Endoscopy. 2000 May;32(5):389-93 [10817178.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] J Surg Oncol. 1998 Nov;69(3):162-7 [9846503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • (PMID = 19347361.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1
  •  go-up   go-down


72. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis.
  • Normal liver tissue, 5 cirrhosis with ductular reaction, 5 focal nodular hyperplasia, 5 bile duct hamartomas, 5 bile duct adenomas, and 45 intrahepatic cholangiocarcinomas from Caucasian patients were studied.
  • Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003).
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


73. Kolb A, Kleeff J, Frohlich B, Werner J, Friess H, Büchler MW: Resection of the intrapancreatic bile duct preserving the pancreas. J Hepatobiliary Pancreat Surg; 2009;16(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of the intrapancreatic bile duct preserving the pancreas.
  • Benign neoplasms of the distal bile duct are rare, but pose a therapeutic challenge.
  • Here, we present a case of an intrapancreatic benign neuroendocrine tumor that was resected by performing a pancreas-preserving distal bile duct resection.
  • First, a duodenotomy was carried out and a probe was inserted into the pancreatic duct to avoid inadvertent injury.
  • Subsequently, the bile duct was divided proximal the lesion and dissected towards the ampulla.
  • Pancreatic parenchyma was dissected dorsally and closed using absorbable interrupted sutures.
  • In conclusion, pancreas-preserving distal bile duct resection might be an option for intrapancreatic benign lesions of the distal bile duct that would otherwise require a partial pancreaticoduodenectomy.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19089312.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Kobayashi G, Fujita N, Noda Y, Ito K, Horaguchi J, Takasawa O, Akaishi S, Tsuchiya T, Kobari M: Mode of progression of intraductal papillary-mucinous tumor of the pancreas: analysis of patients with follow-up by EUS. J Gastroenterol; 2005 Jul;40(7):744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mode of progression of intraductal papillary-mucinous tumor of the pancreas: analysis of patients with follow-up by EUS.
  • BACKGROUND: We investigated the mode of progression of intraductal papillary-mucinous neoplasm of the pancreas (IPMN) in patients who underwent follow-up in order to elucidate the characteristics of malignancy and to establish an effective treatment strategy.
  • METHODS: Fifty-one patients with IPMN (branch-duct type, 47; main-duct type, 4) who had undergone follow-up study by endoscopic ultrasonography (EUS) were included (mean follow-up duration, 41.0+/-32.3 months; average number of EUS examinations performed during follow-up, 4.4).
  • RESULTS: Of the patients with the branch-duct type, only 2% showed enlargement of the dilated branches.
  • In the main-duct-type group, an increase in size of the main pancreatic duct (MPD) was observed in 75% of the patients.
  • CONCLUSIONS: Patients with branch-duct type IPMNs without papillary protrusions or TSS are not immediate candidates for surgery.
  • Those who have small papillary protrusions have a benign course.
  • It is recommended that patients with the large branch-duct type with TSS should undergo surgery.
  • Attention should be paid to the entire pancreas when performing follow-up examinations in patients with branch-duct type IPMN, as invasive ductal adenocarcinoma can develop at a site in the pancreas different from that of the IPMN.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / physiopathology. Endosonography. Pancreatic Neoplasms / diagnostic imaging. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnostic imaging. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / physiopathology. Adenocarcinoma, Mucinous / surgery. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Disease Progression. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Pancreatectomy / methods. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Jul;40(7):773-4 [16082600.001]
  • [Cites] Gastrointest Endosc. 1997 Mar;45(3):268-76 [9087833.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1996-2000 [9951853.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 May;91(5):1003-15 [8196194.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1807-17 [11745253.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):962-6 [11490849.001]
  • [Cites] Jpn J Cancer Res. 1991 Oct;82(10):1057-60 [1955373.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000 [13362715.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • (PMID = 16082592.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, Berry DP, Dennison AR: Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci; 2008 Dec;53(12):3213-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.
  • BACKGROUND: Carbohydrate antigen 19.9 (CA19.9), a tumor marker for malignancies of the hepatobiliary tract and pancreas, has frequently been shown to be deranged in a number of non-malignant conditions that are associated with jaundice.
  • This study aims to demonstrate the correlation between CA19.9 and serum bilirubin concentration in patients with benign conditions and to determine the frequency of a false-positive increase in CA19.9 in patients being investigated for potential HPB malignancies.
  • METHODS: This is a retrospective review of 83 consecutive patients presenting with an abnormal CA19.9 and radiological or clinical features suggestive of HPB malignancy subsequently shown to have benign disease.
  • Adjusting CA19.9 according to bilirubin levels is likely to improve the specificity of this antigen in the differential diagnosis of benign and malignant HPB diseases and its reliability in the monitoring of disease response to chemotherapy.
  • [MeSH-major] Bile Duct Diseases / blood. Bilirubin / blood. CA-19-9 Antigen / blood. Pancreatitis / blood

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]
  • [Cites] J Clin Lab Anal. 2007;21(2):103-6 [17385665.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1941-6 [10406263.001]
  • [Cites] J Clin Gastroenterol. 2007 Jan;41(1):115-7 [17198074.001]
  • [Cites] JOP. 2007 May 09;8(3):335-43 [17495364.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Feb;19(2):167-9 [17273004.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] JOP. 2007 Mar 10;8(2):191-7 [17356242.001]
  • [Cites] Dig Dis Sci. 1989 Oct;34(10):1640-2 [2791822.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):142-7 [17262731.001]
  • [Cites] Endoscopy. 2007 Aug;39(8):720-4 [17661248.001]
  • [Cites] Int J Urol. 2005 Feb;12(2):214-6 [15733120.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1013-6 [10737382.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):29271-8 [7961897.001]
  • [Cites] Am J Clin Pathol. 2007 Mar;127(3):436-40 [17276945.001]
  • [Cites] Eur J Clin Invest. 1992 Dec;22(12):800-4 [1478251.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1125-7 [17342388.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):289-93 [17226911.001]
  • [Cites] J Surg Res. 2007 Jun 1;140(1):31-5 [17418869.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1108:359-71 [17893999.001]
  • [Cites] World J Gastroenterol. 2007 Oct 28;13(40):5357-9 [17879406.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):195-9 [15999098.001]
  • (PMID = 18465243.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


76. Riddle ND, Quigley BC, Browarsky I, Bui MM: Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature. Case Rep Med; 2010;2010:252364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature.
  • Primary pancreatic leiomyosarcoma is extremely rare, and to the best of our knowledge only 30 cases have been reported in the world literature since 1951.
  • Our case represents the first to have a clear origin from the main pancreatic duct.
  • The tumor clearly originated from the pancreatic duct wall, filled and expanded the duct lumen, and was covered with a layer of benign biliary epithelium.
  • To our knowledge, this represents the first reported case demonstrating clear origin of a leiomyosarcoma from the pancreatic duct.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tunis Med. 2005 May;83(5):288-91 [16044903.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Curr Surg. 2004 Nov-Dec;61(6):572-5 [15590026.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):548-51 [15661250.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):22-6 [15885579.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1226-9 [16343220.001]
  • [Cites] Urology. 2006 Feb;67(2):424.e13-424.e15 [16461113.001]
  • [Cites] J Foot Ankle Surg. 2006 Mar-Apr;45(2):127-30 [16513508.001]
  • [Cites] No Shinkei Geka. 2006 Apr;34(4):409-13 [16613223.001]
  • [Cites] Int Surg. 2005 Nov-Dec;90(5):262-5 [16625943.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):137-41 [16330234.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):466-70 [16872443.001]
  • [Cites] Actas Urol Esp. 2006 Jun;30(6):638-40 [16921844.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Oct;263(10):929-34 [16804717.001]
  • [Cites] Arch Esp Urol. 2006 Sep;59(7):728-31 [17078398.001]
  • [Cites] Arch Esp Urol. 2006 Nov;59(9):908-10 [17190216.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):628-33 [17451590.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):634-7 [17451591.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):963-77 [17574946.001]
  • [Cites] Obstet Gynecol Surv. 2007 Jul;62(7):480-6 [17572920.001]
  • [Cites] World J Gastroenterol. 2008 May 14;14(18):2942-5 [18473429.001]
  • [Cites] Pancreas. 2008 Aug;37(2):230-1 [18665093.001]
  • [Cites] Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):158-61 [18720751.001]
  • [Cites] Korean J Radiol. 2007 Nov-Dec;8(6):541-4 [18071285.001]
  • [Cites] HPB (Oxford). 2002;4(3):145-8 [18332943.001]
  • [Cites] Radiat Med. 1999 May-Jun;17(3):239-41 [10440114.001]
  • [Cites] Abdom Imaging. 1999 May-Jun;24(3):299-300 [10227898.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2352-8 [10357405.001]
  • [Cites] Clin Lab Haematol. 1999 Jun;21(3):219-24 [10448606.001]
  • [Cites] Int J Pancreatol. 1999 Dec;26(3):193-9 [10732297.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):189-92 [15221604.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Apr;96(4):286-7 [15259151.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):433-4 [15332041.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):690-2 [16053897.001]
  • (PMID = 20589089.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892659
  •  go-up   go-down


77. Niedergethmann M, Grützmann R, Hildenbrand R, Dittert D, Aramin N, Franz M, Dobrowolski F, Post S, Saeger HD: Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg; 2008 Oct;32(10):2253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1996 and 2006, a total of 1424 pancreatic resections were performed in the University Hospitals Dresden and Mannheim.
  • Pathologists of both institutions reviewed the IPMN diagnoses and other with cystic or solid tumor diagnoses.
  • Because the preoperative diagnostic methods are not sensitive enough to differentiate between benign and malignant lesions, surgery is advocated for all main duct IPMN, because they have a high malignant potential.
  • For branch duct IPMN, surgery is advocated if the lesion is symptomatic, >3 cm, or has enlarged nodules.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Carcinoma, Papillary. Postoperative Complications / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Pancreas. 2007 Mar;34(2):197-204 [17312458.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Eur J Surg. 2001 Feb;167(2):115-9 [11266250.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1041-7 [10931048.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Eur J Surg. 2002;168(12):707-12 [15362580.001]
  • [Cites] Pancreas. 2004 Apr;28(3):235-40 [15084963.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • [Cites] Eur J Surg. 2002;168(6):339-44 [12428871.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):175-83 [15238891.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Med Chir Dig. 1975;4(3):163-6 [1219233.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):462-7 [16509876.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • (PMID = 18668283.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


78. Sugimoto M, Yasuda H, Koda K, Suzuki M, Yamazaki M, Tezuka T, Kosugi C, Higuchi R, Takenoue T, Yamamoto S, Watayo Y, Yagawa Y, Tsuchiya T: Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms. Hepatogastroenterology; 2008 Jan-Feb;55(81):270-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Less invasive pancreatic head resection, such as duodenum-preserving pancreatic head resection (DPPHR) has been introduced for the treatment of pancreatoduodenal lesions, especially for benign conditions, for reducing surgical stress and maintaining exocrine and endocrine function of the residual pancreas in consideration of postoperative quality of life (QOL).
  • METHODOLOGY: We investigated the feasibility of a new technique employing three-dimensional (3D) virtual pancreatography using multi-detector CT (MDCT) with carbon dioxide (CO2) gas as a negative contrast agent for detection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas requiring minimally invasive surgery.
  • Endoscopic retrograde pancreatography (ERP) showed multiple cystic lesions in the head-uncinate process with mild dilatation in the remaining pancreatic duct.
  • For localizing diagnosis of these small and multiple pancreatic cysts, we placed an endoscopic pancreatic stent (EPS), and MDCT with injection of CO2 via EPS was examined for the virtual CO2 pancreatography, consisting of OsiriX software system employing 3D virtual anatomic reconstruction with CO2 gas as a negative contrast agent.
  • There was no residual pancreatic cyst and tumor after surgery.
  • The resected tumor was diagnosed as branch duct type intraductal papillary mucinous adenocarcinoma.
  • According to our minimally invasive DPPHR obtained by virtual CO2 pancreatography, the pancreatic endocrine and exocrine functions of this patient were maintained at almost the same levels as those in his preoperative status.
  • CONCLUSIONS: Our new technique of virtual CO2 MDCT pancreatography is a feasible procedure for preservation of the remnant pancreatic function.
  • This is the first report of virtual CO2 pancreatography providing minimally invasive pancreatic surgery.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Carbon Dioxide. Cholangiopancreatography, Endoscopic Retrograde. Dilatation, Pathologic. Feasibility Studies. Humans. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507123.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


79. Calculli L, Pezzilli R, Fiscaletti M, Casadei R, Brindisi C, Gavelli G: Exocrine pancreatic function assessed by secretin cholangio-Wirsung magnetic resonance imaging. Hepatobiliary Pancreat Dis Int; 2008 Apr;7(2):192-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exocrine pancreatic function assessed by secretin cholangio-Wirsung magnetic resonance imaging.
  • BACKGROUND: Magnetic resonance cholangiopancreatography (MRCP) is useful to assess exocrine pancreatic function by combining rapid imaging acquisition with the administration of secretin, a gastrointestinal hormone that stimulates the secretion of bile and pancreatic juice.
  • This study aimed to determine whether MRCP with secretin administration is able to simultaneously detect alterations of both the pancreatic ducts and exocrine pancreatic function.
  • METHODS: All subjects older than 18 years who underwent magnetic resonance imaging (MRI) and cholangio-Wirsung magnetic resonance imaging (CWMRI) for suspicion of benign or malignant pancreatic diseases from January 2006 to December 2006 were enrolled in the study.
  • Of the 87 patients, 39 had a normal pancreas on imaging, 20 had an intrapapillary mucinous tumor (IPMT), and the rest had chronic pancreatitis (7), serous cystadenoma (6), a previous attack of acute biliary pancreatitis (5), congenital ductal abnormalities (5), mucinous cystadenoma (3), previous pancreatic head resection for autoimmune pancreatitis (1), or cholangiocarcinoma (1).
  • Morphologically, we found two pseudocysts (one of the 7 patients with chronic pancreatitis, and one of the 5 patients after an attack of acute pancreatitis; the latter pseudocyst communicated with the main pancreatic duct).
  • The only pancreatic diseases which impaired the exocrine pancreatic secretion stimulated by secretin were chronic pancreatitis (57.1% of the patients, grade 0-1) and the IPMT mixed type in 2 of the 4 patients was grade 1.
  • CONCLUSION: Secretin MRCP is a useful technique to simultaneously detect the presence of alterations of the pancreatic ducts and exocrine pancreatic function.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance / methods. Pancreas, Exocrine / metabolism. Pancreatic Diseases / metabolism. Pancreatic Ducts / pathology. Secretin

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397857.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 1393-25-5 / Secretin
  •  go-up   go-down


80. Kim SC, Park KT, Lee YJ, Lee SS, Seo DW, Lee SK, Kim MH, Jang SJ, Byun JH, Han DJ: Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg; 2008;15(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center.
  • BACKGROUND/PURPOSE: Appropriate surgical treatment strategies based on clinicopathological findings are unavailable for intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • We investigated the clinical features of pancreatic IPMN in a single-center database in order to design an optimal surgical strategy.
  • RESULTS: Most of the invasive carcinomas in these patients were detected as the main-duct type (88.5%).
  • The type of tumor (main-duct type vs branched-duct type), the tumor size, and the dilated duct size were significant predictive factors associated with malignancy.
  • The relative risk of malignancy was greatest at 13-mm or more ductal dilation in the main-duct type (Odds ratio, 4.1), at 35-mm or more tumor size (Odds ratio, 7.6), and for main-duct type (Odds ratio, 3.9).
  • Major pancreatic resections such as total pancreatectomy and pancreatoduodenectomy were performed in 14.5% and 69% of the patients, respectively.
  • However, significant recurrence did not occur in patients with a benign IPMN lesion which remained at the resection margin.
  • The overall postoperative survival rate at 5 years was 98.2% for benign IPMN and 65.3% for malignant IPMN.
  • CONCLUSIONS: Function-preserving strategies, based on the clinical status of the patient, are necessary in order to avoid possible severe metabolic complications following extended pancreatectomy in patients with benign IPMN because of the low recurrence rate and good prognosis of this entity, irrespective of margin status.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Mucins / secretion. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392712.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


81. Fan F, Lai EC, Xie F, Yang JM, Xu F, Kan T, Shen RX, Yang XY, Lau Wan Y, Wu MC: Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy. Hepatogastroenterology; 2010 May-Jun;57(99-100):635-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: Forty patients who underwent pancreatic resection for IPMN at a single tertiary center between January 1996 and March 2008 were retrospectively analyzed.
  • Patients with benign IPMN had 1-, 3-, and 5-year overall survival rates of 100%, 94.1%, and 88.2%, respectively and 1-, 3-, and 5-year disease-free survival rates of 100%, 94.1%, and 88.2%, respectively.
  • Abdominal pain, jaundice, main-duct or mixed type, tumor size, mural nodule and size of mural nodule, were predictive of malignant IPMN by univariate analysis, and size of mural nodule was identified as the only independent predictive factor for malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698241.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


82. Zhou L, Lu Z, Yang A, Deng R, Mai C, Sang X, Faber KN, Lu X: Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics; 2007 Apr;7(8):1345-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic analysis of human pancreatic juice: methodological study.
  • Pancreatic cancer is the most lethal of all the common malignancies.
  • Here, we optimized and applied a proteome analysis of human pancreatic juice to identify biomarkers for pancreatic cancer.
  • Pancreatic juice samples, devoid of blood or bile contamination, were collected from patients with pancreatic cancer (n = 5), benign pancreatic diseases (n = 6), or cholelithiasis (n = 3) during endoscopic retrograde cholangiopancreatography (ERCP).
  • After ultramembrane centrifugation sample preparation, pancreatic juice proteins were separated by 2-DE and identified by MALDI-TOF-MS.
  • A 2-DE dataset of pancreatic juice from patients with cholelithiasis was established, consisting of 76 protein spots representing 22 different proteins.
  • Disease-associated obstruction of the pancreatic duct strongly effected the protein composition of pancreatic juice.
  • Concurrently, pancreatic juice from patients with pancreatic cancer was compared to nonmalignant controls with comparable obstruction of pancreatic ducts.
  • Seven protein spots were identified that consistently appeared at changed levels in pancreatic juice from patients with pancreatic cancer.
  • In conclusion, comparative proteomic analysis of human pancreatic juice can be used to identify biomarkers of pancreatic cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pancreatic Juice / chemistry. Pancreatic Neoplasms / metabolism. Proteome / analysis. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443640.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 1393-25-5 / Secretin
  •  go-up   go-down


83. Park JK, Ryu JK, Lee KH, Lee JK, Yoon WJ, Lee SH, Yoo JW, Woo SM, Lee GY, Lee CH, Kim YT, Yoon YB: Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer. Pancreas; 2007 Oct;35(3):e9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer.
  • OBJECTIVES: Percutaneous fine-needle aspiration cytology or biopsy has been used for pathological confirmation in pancreatic cancer.
  • Although endoscopic retrograde cholangiopancreatography (ERCP)-guided pancreatic duct brush cytology is less invasive, its reliability is very low.
  • Recently, aberrantly methylated genes were reported in pancreatic cancer tissue.
  • METHODS: We enrolled pathologically proven 33 pancreatic cancer patients and 22 benign pancreaticobiliary disease patients.
  • The ERCP-guided pancreatic duct brush cytology samples were obtained.
  • RESULTS: Pancreatic cancer cytology samples had statistically significant higher levels of NPTX2 methylation compared with benign diseases, and the optimal cutoff value of NPTX2 methylation was 1.2%.
  • The sensitivity was 87%, and specificity was 80%, whereas pathological examination by ERCP-guided pancreatic duct brush cytology had a sensitivity of 38%.
  • CONCLUSIONS: The quantitative analysis of NPTX2 hypermethylation may play a role in making highly sensitive and less invasive diagnosis of pancreatic cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. C-Reactive Protein / genetics. Carcinoma, Pancreatic Ductal / diagnosis. CpG Islands. DNA Methylation. DNA, Neoplasm / analysis. Neoplasm Proteins / genetics. Nerve Tissue Proteins / genetics. Pancreatic Neoplasms / diagnosis. Polymerase Chain Reaction / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Computer Systems. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Pancreatic Diseases / diagnosis. Pancreatic Diseases / metabolism. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895837.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / neuronal pentraxin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


84. Fukunaga N, Ishikawa M, Minato T, Yamamura Y, Ishikura H, Ichimori T, Kimura S, Sakata A, Fujii Y: Lymphoepithelial cyst of the pancreas that was difficult to distinguish from branch duct-type intraductal papillary mucinous neoplasm: report of a case. Surg Today; 2009;39(10):901-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelial cyst of the pancreas that was difficult to distinguish from branch duct-type intraductal papillary mucinous neoplasm: report of a case.
  • The tumor markers, including DUPAN 2, SPAN-1, and carbohydrate antigen 19-9, were within the normal ranges.
  • Endoscopic retrograde cholangiopancreatography showed that the main pancreatic duct was normal.
  • Based on these findings, we suspected a branch duct type intraductal papillary mucinous neoplasm.
  • Pathologically, the cyst wall was lined with squamous epithelium surrounded by abundant lymphoid tissue with follicles, consistent with a lymphoepithelial cyst of the pancreas, which is an unusual benign cyst.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Cyst / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):221-4 [7890845.001]
  • [Cites] Pathologe. 1985 Jul;6(4):217-9 [4048076.001]
  • [Cites] Am J Surg. 1995 Jul;170(1):27-32 [7793490.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):342-5 [15019932.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Abdom Imaging. 1998 Mar-Apr;23 (2):185-7 [9516512.001]
  • [Cites] Am J Surg Pathol. 1987 Nov;11(11):899-903 [3674287.001]
  • [Cites] Surg Today. 2008;38(1):68-71 [18085369.001]
  • [Cites] JOP. 2008 Jan 08;9(1):46-9 [18182743.001]
  • [Cites] JOP. 2008 Mar 08;9(2):230-4 [18326936.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):501-6 [17063496.001]
  • (PMID = 19784732.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Leung TK, Lee CM, Shen LK, Chen YY: Differential diagnosis of cystic lymphangioma of the pancreas based on imaging features. J Formos Med Assoc; 2006 Jun;105(6):512-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma is a benign tumor, which is a consequence of lymphatic malformation with blockage of lymphatic flow.
  • It is always a challenge to differentiate the lesion from other possible cystic-like pancreatic neoplasms.
  • Differential diagnosis of cystic lymphangioma from other cystic-like tumors of the pancreas can be performed based on their imaging characteristics, including presence of septa, cystic or wall calcification, soft tissue, wall thickness, single or multiple loculation, and dilatation of the pancreatic duct.

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801041.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


86. Oku T, Maeda M, Wada Y, Waga E, Ono K, Nagamachi Y, Fujii S, Fujita M, Misu K, Senmaru N, Suzuki Y, Nagashima K, Niitsu Y: Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology. JOP; 2007;8(2):206-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology.
  • CONTEXT: An intraductal oncocytic papillary neoplasm is a rare pancreatic tumor which was first described by Adsay et al. in 1996.
  • Microscopically, the cyst was lined by columnar epithelium similar to pancreatic duct epithelium, and the nodular projection consisted of arborizing papillary structures, lined by plump cells with abundant eosinophilic cytoplasm.
  • The cellular atypism was mild and the proliferating index was low, compatible with adenoma of an intraductal oncocytic papillary neoplasm.
  • Although no ovarian type stroma was identified, in our case, no communication to main pancreatic duct (located in the pancreatic body) and rapid growth by intracystic hemorrhage were clinical characteristics of a mucinous cystic neoplasm, but not IPMN.
  • CONCLUSION: With only 17 cases reported to date, the clinical and pathological details of an intraductal oncocytic papillary neoplasm are still unclear.
  • To our knowledge, this is the first case report of an intraductal oncocytic papillary neoplasm with the clinical characteristics of a mucinous cystic neoplasm.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356245.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Kitagawa H, Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Akimori T, Kohsaki T, Miyaji E, Onishi S, Araki K: Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy. Int J Gastrointest Cancer; 2006;37(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 8 mo postpartum, she became aware of an upper abdominal tumor.
  • Endoscopic retrograde pancreatography showed no connection between the main pancreatic duct and the cystic lesion.
  • The patient underwent tumor resection at 11 mo postpartum.
  • Pathological examination of the tumor revealed mucin-producing columnar epithelial cells lining the cystic wall with ovarian-type stromal tissue and no findings indicative of malignancy, giving a diagnosis of mucinous cystic adenoma of the pancreas.
  • Postpartum rapid growth of a benign mucinous cystic neoplasm might be linked to the production of female sex hormones during lactation.
  • [MeSH-major] Adenoma / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] World J Surg Oncol. 2005 Sep 07;3:59 [16146567.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):282-7 [15780564.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):203-5 [15221374.001]
  • (PMID = 17290080.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Langer P, Bartsch DK, Fendrich V, Kann PH, Rothmund M, Zielke A: [Minimal-invasive operative treatment of organic hyperinsulinism]. Dtsch Med Wochenschr; 2005 Mar 11;130(10):514-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Insulinomas are small, solitary and benign endocrine pancreatic tumours, causing organic hyperinsulinism by autonomous insulin-secretion.
  • THERAPY AND COURSE: Laparoscopic resection of the tumor was attempted and accomplished in both patients.
  • The young man underwent laparoscopic enucleation of the tumor, while the 50 year old man underwent left sided laparoscopic resection of the pancreas because the tumor was adjacent to the pancreatic duct.
  • [MeSH-minor] Adolescent. Endosonography. Humans. Insulinoma / complications. Insulinoma / surgery. Insulinoma / ultrasonography. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Pancreas / ultrasonography. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744643.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Sugiyama M, Suzuki Y, Abe N, Mori T, Atomi Y: Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2008;43(3):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct entity characterized by papillary proliferations of mucin-producing epithelial cells with excessive mucus production and cystic dilatation of the pancreatic ducts.
  • IPMNs are classified into main duct and branch duct types, based on the site of tumor involvement.
  • The postoperative 5-year survival rate is nearly 100% for benign tumors and noninvasive carcinoma, and approximately 60% for invasive carcinoma.
  • A main duct type IPMN should be resected.
  • Surgical treatment is indicated for a branch duct IPMN with suspected malignancy (tumor diameter > or = 30 mm, mural nodules, dilated main pancreatic duct, or positive cytology) or positive symptoms.
  • IPMNs are associated with a high incidence of extrapancreatic malignancies and pancreatic ductal carcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2001-8 [9951854.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1166-9 [12045867.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Am J Gastroenterol. 1998 Feb;93(2):156-9 [9468232.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):251-5 [12620565.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] J Gastroenterol. 2002;37(10):868-73 [12424574.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 18373159.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 37
  •  go-up   go-down


90. Shimura T, Suehiro T, Suzuki H, Mochida Y, Okada K, Araki K, Kuwano H: Preoperative endoscopic pancreatic stenting for prophylaxis of pancreatic duct disruption during extirpation of a pancreatic head tumor. Am J Surg; 2007 Oct;194(4):553-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative endoscopic pancreatic stenting for prophylaxis of pancreatic duct disruption during extirpation of a pancreatic head tumor.
  • BACKGROUND: Pancreatic fistula is a major problem in minimal invasive surgery of the pancreas.
  • To prevent the disruption of the pancreatic duct, the surgeon must recognize the site of the pancreatic duct exactly.
  • METHODS: We reviewed the cases of 7 patients who underwent preoperative endoscopic pancreatic stenting for the prophylaxis of pancreatic fistula development after enucleation of a benign pancreatic head tumor.
  • RESULTS: Preoperative endoscopic pancreatic stenting was successfully performed in all 7 patients.
  • None of the patients developed a pancreatic fistula.
  • CONCLUSIONS: Preoperative pancreatic duct stenting is a feasible, effective, and safe technique to prevent pancreatic duct disruption during enucleation of a benign tumor of the pancreatic head.
  • [MeSH-major] Endoscopy, Digestive System. Intraoperative Complications / etiology. Intraoperative Complications / prevention & control. Pancreatectomy / adverse effects. Pancreatectomy / methods. Pancreatic Ducts / injuries. Pancreatic Fistula / etiology. Pancreatic Fistula / prevention & control. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Stents

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826078.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Khalid A: Differentiating neoplastic from benign lesions of the pancreas: translational techniques. Clin Gastroenterol Hepatol; 2009 Nov;7(11 Suppl):S55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating neoplastic from benign lesions of the pancreas: translational techniques.
  • There has been substantial recent progress in our ability to image and sample the pancreas leading to the improved recognition of benign and premalignant conditions of the pancreas such as autoimmune pancreatitis (AIP) and mucinous lesions (mucinous cystic neoplasms [MCN] and intraductal papillary mucinous neoplasms [IPMN]), respectively.
  • Clinically relevant and difficult situations that continue to be faced in this context include differentiating MCN and IPMN from nonmucinous pancreatic cysts, the early detection of malignant degeneration in MCN and IPMN, and accurate differentiation between pancreatic cancer and inflammatory masses, especially AIP.
  • Aspirates from pancreatic cysts are often paucicellular further limiting the accuracy of cytology.
  • Because the development of pancreatic cancer and malignant degeneration in MCN and IPMN is associated with well studied genetic insults including oncogene activation (eg, k-ras), tumor suppressor gene losses (eg, p53, p16, and DPC4), and genome maintenance gene mutations (eg, BRCA2 and telomerase), detecting these molecular abnormalities may aid in improving our diagnostic accuracy.
  • A number of studies have shown the utility of testing clinical samples from pancreatic lesions and bile duct strictures for these molecular markers of malignancy to differentiate between cancer and inflammation.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896100.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


92. Ishizaki Y, Yoshimoto J, Miwa K, Sugo H, Kawasaki S: Safety of prolonged intermittent pringle maneuver during hepatic resection. Arch Surg; 2006 Jul;141(7):649-53; discussion 654
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Resections were performed for metastatic carcinoma in 19 patients, hepatocellular carcinoma in 7 patients, hilar bile duct carcinoma in 3 patients, intrahepatic cholangiocarcinoma in 1 patient, combined hepatocellular carcinoma and cholangiocarcinoma in 1 patient, undifferentiated embryonal sarcoma in 1 patient, carcinoid tumor in 1 patient, and benign mucinous cystic tumor in 1 patient.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847234.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Dinter DJ, Aramin N, Weiss C, Singer C, Weisser G, Schoenberg SO, Post S, Niedergethmann M: Prediction of anastomotic leakage after pancreatic head resections by dynamic magnetic resonance imaging (dMRI). J Gastrointest Surg; 2009 Apr;13(4):735-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of anastomotic leakage after pancreatic head resections by dynamic magnetic resonance imaging (dMRI).
  • PURPOSE: The texture of the pancreatic tissue is a main risk factor for leakage after pancreaticojejunostomy and can be differentiated using dynamic contrast enhanced magnetic resonance imaging (dMRI).
  • In order to identify risk factors and to assess the role of pancreatic dMRI, a cohort of patients was retrospectively reviewed.
  • All patients received pancreatic head resection with a duct-to-mucosa pancreaticojejunostomy.
  • Patients with a rapid increase had significantly better preoperative American Society of Anesthesiologists staging, lower carbohydrate antigen 19-9 values, and smaller tumor sizes.
  • Most of them had not only benign tumors but also longer postoperative hospital stay, in comparison to patients with delayed perfusion (SI(ratio) <1.1).
  • CONCLUSION: dMRI with SI(ratio) calculation provided reliable information for the prediction of pancreatic texture.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] Top Magn Reson Imaging. 2007 Dec;18(6):421-9 [18303400.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):18-24 [9208956.001]
  • [Cites] Surgery. 2007 Apr;141(4):420-6 [17383518.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):951-9 [15585382.001]
  • [Cites] Eur J Surg. 2001 Feb;167(2):115-9 [11266250.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):931-7; discussion 937-9 [17122618.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2456-61 [15832417.001]
  • [Cites] Ann Surg. 1988 Jan;207 (1):39-47 [3276272.001]
  • [Cites] World J Surg. 2002 Jan;26(1):99-104 [11898041.001]
  • [Cites] J Gastrointest Surg. 2003 Jul-Aug;7(5):672-82 [12850681.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):201-8 [14769305.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jan;23(1):23-33 [18171340.001]
  • [Cites] Dig Surg. 2004;21(1):54-9 [14707394.001]
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1163-71; discussion 1171-3 [16269388.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):913-24 [7660254.001]
  • [Cites] Cancer Imaging. 2006 Dec 20;6:199-203 [17208676.001]
  • [Cites] Radiology. 2008 Apr;247(1):115-21 [18292476.001]
  • [Cites] Magn Reson Med. 2005 Feb;53(2):249-55 [15678552.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):171-83 [17236843.001]
  • [Cites] Eur J Surg. 2002;168(12):707-12 [15362580.001]
  • [Cites] Ann Surg. 2002 Feb;235(2):240-5 [11807364.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1124-9 [12143218.001]
  • [Cites] Rofo. 1999 Jun;170(6):528-33 [10420901.001]
  • [Cites] Pancreas. 2007 Oct;35(3):273-5 [17895850.001]
  • [Cites] J Am Coll Surg. 2006 May;202(5):723-31 [16648011.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):419-29 [10973392.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):175-83 [15238891.001]
  • [Cites] J Dig Dis. 2007 Aug;8(3):128-32 [17650223.001]
  • [Cites] Rofo. 1995 May;162(5):396-403 [7772761.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Br J Surg. 2004 May;91(5):595-600 [15122611.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1451-8; discussion 1459 [17710506.001]
  • [Cites] Pancreas. 2007 Nov;35(4):361-5 [18090244.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):490-8 [16627213.001]
  • [Cites] J Magn Reson Imaging. 2004 Dec;20(6):990-7 [15558558.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Surg Endosc. 2006 Apr;20 Suppl 2:S446-9 [16557419.001]
  • [Cites] Anticancer Res. 1991 Sep-Oct;11(5):1831-48 [1685076.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 19057965.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


94. Bloomston M, Kneile J, Butterfield M, Dillhoff M, Muscarella P, Ellison EC, Melvin WS, Croce CM, Pichiorri F, Huebner K, Frankel WL: Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol; 2009 Aug;16(8):2331-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Wwox has been understudied in pancreatobiliary cancers, especially in relation to other involved tumor suppressors.
  • We have assessed the status of the Fhit and Wwox proteins encoded by DNA damage susceptible chromosome fragile sites encompassed by FHIT and WWOX tumor suppressor genes.
  • METHODS: Pancreatic, gallbladder and ampullary cancers, normal pancreas, chronic pancreatitis, and benign gallbladder specimens were stained for expression of Fhit, Fhit effector protein Fdxr, Wwox, and other tumor suppressors by immunohistochemistry, and comparisons were made between benign and malignant tissue.
  • RESULTS: Fhit and Wwox were ubiquitously expressed in benign samples and significantly and coordinately reduced in pancreatic, gallbladder, and ampullary cancers.
  • In pancreatic cancers, Fdxr expression was positively correlated with Fhit and Wwox expression.
  • Neither Fhit nor Wwox expression correlated with expression of other tumor suppressors or with clinicopathologic characteristics measured.
  • CONCLUSION: Loss of Fhit and Wwox expression does not predict tumor progression or patient survival, suggesting that loss of expression of genes at the exquisitely replication stress sensitive chromosome fragile regions is an early event in the pathogenesis of cancers of the gallbladder, pancreas, and ampulla.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Oct 17;21(47):7195-204 [12370809.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1111-7 [11590433.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):131-8 [12969785.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1605-14 [15073846.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2459-65 [15073125.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3053-8 [15131042.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:7 [12537585.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4347-50 [8813121.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1583-7 [9563464.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1308-14 [10096564.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):471-8 [15998374.001]
  • [Cites] Surg Today. 2006;36(1):1-5 [16378185.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):45-50 [16506374.001]
  • [Cites] Dig Surg. 2006;23(1-2):74-9 [16717472.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):211-7 [17080236.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):12-22 [17142102.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):110-7 [17164758.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Bull Cancer. 2007 Mar;94(3):E8-11 [17371765.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1018-26 [17373735.001]
  • [Cites] Cancer Lett. 2007 May 18;250(1):100-6 [17084965.001]
  • [Cites] J Gastrointest Surg. 2007 May;11(5):578-88 [17468917.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Cell Physiol. 2007 Aug;212(2):307-10 [17458891.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6115-21 [17947476.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):31-5 [16775119.001]
  • [Cites] Cancer Biol Ther. 2007 Oct;6(10):1592-9 [17912030.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] J Biol Chem. 2008 May 16;283(20):13736-44 [18319262.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1370-6 [18460020.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):239-43 [10679912.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):60-6 [12557261.001]
  • (PMID = 19434452.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115965; United States / NCI NIH HHS / CA / R01 CA115965-03; United States / NCI NIH HHS / CA / CA133250-01; United States / NCI NIH HHS / CA / R01 CA132453-02; United States / NCI NIH HHS / CA / CA132453; United States / NCI NIH HHS / CA / K12 CA133250-01; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / CA132453-02; United States / NCI NIH HHS / CA / CA115965-03; United States / NCI NIH HHS / CA / CA133250; United States / NCI NIH HHS / CA / R01 CA115965; United States / NCI NIH HHS / CA / R01 CA132453
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ NIHMS128319; NLM/ PMC2719793
  •  go-up   go-down


95. Lee JH, Lee KT, Park J, Bae SY, Lee KH, Lee JK, Jang KT, Heo JS, Choi SH, Choi DW, Rhee JC: Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms. World J Gastroenterol; 2010 Nov 14;16(42):5353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.
  • The medical records were retrospectively reviewed and immunohistochemical staining for mucin (MUC) in pancreatic tissues was performed.
  • RESULTS: Univariate analysis showed that the following five variables were closely associated with malignant IPMNs preoperatively: absence of extrapancreatic malignancy; symptoms; tumor size > 4 cm; main pancreatic duct (MPD) size > 7 mm; and lymph node enlargement on preoperative computed tomography (CT).
  • No significant differences in the expression of MUC1, MUC2 and MUC5AC were observed between benign and malignant IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Carcinoma, Papillary. Pancreatic Neoplasms. Predictive Value of Tests
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Mucins / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2008;8(6):577-82 [18824881.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] World J Surg. 2010 Apr;34(4):776-83 [20127242.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):109-10 [12080246.001]
  • [Cites] J Pathol. 2002 Aug;197(5):632-7 [12210083.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):610-7; discussion 617-8 [12799331.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):124-32 [15827792.001]
  • [Cites] Pancreas. 2005 May;30(4):e96-102 [15841035.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Pancreas. 2006 Mar;32(2):186-9 [16552339.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Pancreas. 2006 Nov;33(4):391-6 [17079945.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Pancreas. 2009 Jan;38(1):8-16 [18665010.001]
  • (PMID = 21072900.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC2980686
  •  go-up   go-down


96. Hirano S, Kondo S, Tanaka E, Shichinohe T, Suzuki O, Shimizu M, Itoh T: Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas. Hepatogastroenterology; 2009 Mar-Apr;56(90):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This retrospective study evaluated the suitability of computed tomography (CT) to detect malignancy while following patients with branch-type IPMN, most of which are benign and may be treated with observation alone.
  • METHODOLOGY: Forty-two surgical specimens resected from patients with a diagnosis of branch-type IPMN were pathologically classified as benign (n=26), which included hyperplasia and adenoma, or malignant (n=16), including moderate dysplasia or adenocarcinoma.
  • It was compared the differences in the sizes of the tumor and main pancreatic duct (MPD) and the presence of mural nodules on CT between the groups.
  • RESULTS: In the malignant group, it was observed a larger tumor size (47.8 vs. 23.8 mm; p = 0.001) and increased dilation of the MPD (9.3 vs. 5.0 mm; p = 0.001) than those seen in the benign group.
  • Tumor diameter > or =40 mm or MPD diameter >10 mm predicted malignancy with a sensitivity and negative predictive value of 93.8% and 95.7%, respectively.
  • CONCLUSIONS: Either tumor size or MPD dilation detected by CT could predict the majority of malignant branch-type IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Papillary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579633.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. Han J, Lee SK, Park DH, Choi JS, Lee SS, Seo DW, Kim MH: [Treatment outcome after endoscopic papillectomy of tumors of the major duodenal papilla]. Korean J Gastroenterol; 2005 Aug;46(2):110-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Endoscopic papillectomy is reported to be relatively safe and reliable for complete resection of benign tumors of the major duodenal papilla.
  • METHODS: Medical records of 22 consecutive patients with tumor of the major duodenal papilla (10 women, 12 men; mean age 55.8+/-2.8 yrs) who have undergone endoscopic papillectomy were reviewed retrospectively.
  • Endoscopic papillectomy was defined the successful when complete excision of the tumor was achieved.
  • A pancreatic duct stent was placed in 11 patients (50.0%) and was removed after 3 to 39 days.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Sphincterotomy, Endoscopic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118521.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


98. Beger HG, Rau BM, Gansauge F, Poch B: Duodenum-preserving subtotal and total pancreatic head resections for inflammatory and cystic neoplastic lesions of the pancreas. J Gastrointest Surg; 2008 Jun;12(6):1127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-preserving subtotal and total pancreatic head resections for inflammatory and cystic neoplastic lesions of the pancreas.
  • INTRODUCTION: For treatment of inflammatory and benign neoplastic lesions of the pancreatic head, a subtotal or total pancreatic head resection is a limited surgical procedure with the impact of replacing the application of a Whipple procedure.
  • The objective of this work is to describe the technical modifications of subtotal and total pancreatic head resection for inflammatory and neoplastic lesions of the pancreas.
  • The advantages of this limited surgical procedure are the preservation of the stomach, the duodenum and the extrahepatic biliary ducts for treatment of benign lesions of the pancreatic head, papilla, and intrapancreatic segment of the common bile duct.
  • For chronic pancreatitis with an inflammatory mass complicated by compression of the common bile duct or causing multiple pancreatic main duct stenoses and dilatations, a subtotal pancreatic head resection results in a long-lasting pain control.
  • Performing, in addition, a biliary anastomosis or a Partington Rochelle type of pancreatic main duct drainage, respectively, is a logic and simple extension of the procedure.
  • The rationale for the application of duodenum-preserving total pancreatic head resection for cystic neoplastic lesions are complete exstirpation of the tumor and, as a consequence, interruption of carcinogenesis of the neoplasia preventing development of pancreatic cancer.
  • For mono-centric IPMN, MCN, and SCA tumors, located in the pancreatic head, total duodenum-preserving pancreatic head resection can be performed without hospital mortality and resurgery for recurrency.
  • Based on controlled clinical trials, duodenum-preserving pancreatic head resection is superior to the Whipple-type resection with regard to lower postoperative morbidity, almost no delay of gastric emptying, preservation of the endocrine function, lower frequency of rehospitalization, early professional rehabilitation, and establishment of a predisease level of quality of life.
  • CONCLUSION: The limited surgical procedures of subtotal or total pancreatic head resection are simple, safe, ensures free tumour margins and replace in the authors institution the application of a Whipple-type head resection.
  • [MeSH-major] Pancreatic Cyst / surgery. Pancreaticoduodenectomy / methods. Pancreatitis / surgery

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Chirurg. 1980 May;51(5):303-7 [7408575.001]
  • [Cites] Pancreas. 1987;2(6):701-7 [3438308.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):533-5 [9638444.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):512-9; discussion 519-23 [10522721.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):350-8 [7726670.001]
  • [Cites] Chirurg. 1987 Jan;58(1):7-13 [3549190.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):710-5 [15862268.001]
  • [Cites] Surgery. 2003 Jul;134(1):53-62 [12874583.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):213-9 [9488519.001]
  • [Cites] Chirurgie. 1981;107(8):597-604 [7327022.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):771-9 [9860476.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):356-9 [8406305.001]
  • [Cites] Dig Surg. 2001;18(1):21-5 [11244255.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):149-56 [18392707.001]
  • [Cites] Chirurg. 1995 Apr;66(4):350-9 [7634946.001]
  • (PMID = 18299945.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


99. Cheng CL, Fogel EL, Sherman S, McHenry L, Watkins JL, Croffie JM, Gupta SK, Fitzgerald JF, Lazzell-Pannell L, Schmidt S, Lehman GA: Diagnostic and therapeutic endoscopic retrograde cholangiopancreatography in children: a large series report. J Pediatr Gastroenterol Nutr; 2005 Oct;41(4):445-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included biliary pathology (n = 93), pancreatic pathology (n = 111), and chronic abdominal pain of suspected biliary or pancreatic origin (n = 41).
  • The ERCP findings were bile duct stone(s) (n = 29), benign biliary stricture (n = 19), primary sclerosing cholangitis (n = 7), anomalous pancreaticobiliary union (n = 8), choledochal cyst (n = 5), bile duct leak (n = 6), malignant biliary stricture (n = 2), biliary atresia (n = 1), chronic pancreatitis (n = 44), pancreas divisum (n = 26), pancreatic duct stricture with (n = 6) or without (n = 9) leak, pancreatic tumor (n = 1), periampullary adenoma (n = 2), and sphincter of Oddi dysfunction (n = 65).
  • [MeSH-major] Biliary Tract Diseases / diagnosis. Biliary Tract Diseases / therapy. Cholangiopancreatography, Endoscopic Retrograde. Pancreatic Diseases / diagnosis. Pancreatic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205513.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Uehara H, Tatsumi K, Masuda E, Kato M, Kizu T, Ishida T, Takakura R, Takano Y, Nakaizumi A, Ishikawa O, Takenaka A: Scraping cytology with a guidewire for pancreatic-ductal strictures. Gastrointest Endosc; 2009 Jul;70(1):52-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scraping cytology with a guidewire for pancreatic-ductal strictures.
  • BACKGROUND: Strictures of the pancreatic duct may be caused by a variety of underlying pathologic conditions that imaging examinations often fail to define.
  • Conventional procedures for acquisition of a specimen for cytology during ERCP have been limited in their ability to discriminate pancreatic-ductal strictures.
  • OBJECTIVE: Our aim was to discriminate pancreatic-ductal strictures by a new technique of sampling material for cytodiagnosis: scraping cytology with a guidewire.
  • PATIENTS AND METHODS: Eighty-six patients with pancreatic-ductal strictures composed of 71 malignant and 15 benign diseases were evaluated.
  • Malignant diseases included 70 pancreatic carcinomas and 1 endocrine tumor; benign diseases included the following: 7 chronic pancreatitis, 3 autoimmune pancreatitis, 3 idiopathic pancreatic-ductal strictures, and 2 pancreatic cysts.
  • During ERCP, pancreatic juice was collected with a cannula in the main duct just below the stricture after scraping it with a 0.025-inch hydrophilic guidewire.
  • MAIN OUTCOME MEASUREMENTS: Diagnostic sensitivities and specificities of scraping cytology with a guidewire for pancreatic carcinoma.
  • Sensitivities for pancreatic carcinoma in the head, body, and tail of the pancreas were 91%, 100%, and 91%, respectively.
  • Sensitivities for pancreatic carcinoma with a tumor of <20 mm, 21 to 40 mm, 41 to 60 mm, and >61 mm were 95%, 92%, 100%, and 100%, respectively.
  • CONCLUSIONS: Benign or malignant pancreatic-ductal strictures were accurately discriminated by scraping cytology with a guidewire during ERCP.
  • The technique yielded high diagnostic sensitivities in pancreatic carcinoma, regardless of the location or size of the tumor.
  • [MeSH-major] Cytological Techniques / methods. Pancreatic Ducts / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249043.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down